BACKGROUND O
: I-GENE
Ischemic O
heart O
disease O
is O
the I-GENE
primary O
cause O
of I-GENE
morbidity O
and I-GENE
mortality O
among O
diabetics _RARE_
, O
especially O
those O
who O
became O
ill _RARE_
at O
a I-GENE
young O
age O
. I-GENE

More O
importantly _RARE_
, O
this O
fusion O
converted O
a I-GENE
less O
effective O
vaccine O
into O
one O
with O
significant O
potency O
against O
established O
E7 I-GENE
- O
expressing O
metastatic O
tumors O
. I-GENE

Reverse _RARE_
transcription I-GENE
- O
PCR O
analysis O
of I-GENE
mRNA I-GENE
from I-GENE
patients O
shows O
that O
each O
of I-GENE
these O
five O
mutations O
results O
in O
aberrant O
splicing _RARE_
. I-GENE

Using O
the I-GENE
postural _RARE_
and I-GENE
force O
data O
as _RARE_
input O
to O
a I-GENE
3 I-GENE
- O
D O
biomechanical _RARE_
model O
, O
the I-GENE
lumbosacral _RARE_
spinal O
compression O
was O
calculated O
. I-GENE

Sequence O
analysis O
revealed O
significant O
differences O
between O
the I-GENE
5 O
' I-GENE
region O
of I-GENE
the I-GENE
beta I-GENE
subunit I-GENE
gene I-GENE
and I-GENE
the I-GENE
corresponding O
regions O
of I-GENE
the I-GENE
homologous O
GlyR _RARE_
alpha O
subunit I-GENE
genes I-GENE
; O
it O
also O
identified O
a I-GENE
novel O
exon O
( O
exon O
0 O
) O
that O
encodes O
most O
of I-GENE
the I-GENE
5 O
'- I-GENE
untranslated O
portion O
of I-GENE
the I-GENE
GlyR _RARE_
beta I-GENE
mRNA I-GENE
. I-GENE

Therefore O
, O
we O
suggested O
that O
both O
proteins I-GENE
might O
belong O
to O
the I-GENE
PLTP _RARE_
family O
. I-GENE

Influence O
of I-GENE
compression O
therapy O
on O
symptoms O
following O
soft O
tissue I-GENE
injury O
from I-GENE
maximal O
eccentric _RARE_
exercise O
. I-GENE

STAT5A _RARE_
mutations O
in O
the I-GENE
Src I-GENE
homology I-GENE
2 I-GENE
( O
SH2 I-GENE
) O
and I-GENE
SH3 I-GENE
domains I-GENE
did O
not O
alter O
the I-GENE
BTK _RARE_
- O
mediated O
tyrosine I-GENE
phosphorylation O
. I-GENE

In O
the I-GENE
present O
work O
, O
the I-GENE
complete O
genome O
sequences O
of I-GENE
Pyrococcus _RARE_
horikoshii _RARE_
and I-GENE
Pyrococcus _RARE_
abyssi _RARE_
, O
two O
species O
in O
a I-GENE
genus O
of I-GENE
hyperthermophilic _RARE_
archaeon _RARE_
( O
archaebacterium _RARE_
), O
were O
compared O
to O
detect O
large O
genome O
polymorphisms _RARE_
linked O
with O
restriction O
- O
modification O
gene I-GENE
homologs I-GENE
. I-GENE

In O
addition O
, O
these O
patients O
show O
both O
quantitative O
and I-GENE
qualitative O
differences O
in O
their O
infectious O
microbiological _RARE_
spectrum O
, O
mainly O
in O
clean _RARE_
- O
contaminated O
, O
contaminated O
and I-GENE
dirty _RARE_
surgical O
procedures O
. I-GENE

Here O
we O
show O
that O
PKC I-GENE
and I-GENE
p44 I-GENE
/ O
p42MAPK _RARE_
signalings _RARE_
are O
required O
for O
the I-GENE
HBx _RARE_
- O
induced O
Sp1 I-GENE
- O
mediated O
IGF I-GENE
- O
II I-GENE
P4 _RARE_
transcriptional O
activity O
since O
( O
i I-GENE
) O
PKC I-GENE
activation O
by O
PMA O
or O
PKC I-GENE
expression _RARE_
vector O
increases O
Sp1 I-GENE
phosphorylation O
and I-GENE
P4 _RARE_
activity O
in O
HBx _RARE_
- O
transfected O
HepG2 O
cells O
; O
( O
ii O
) O
PKC I-GENE
inhibition O
by O
PKC I-GENE
inhibitor I-GENE
Go6976 _RARE_
reduces O
Sp1 I-GENE
phosphorylation O
, O
P4 _RARE_
activity O
, O
and I-GENE
IGF I-GENE
- O
II I-GENE
mRNA I-GENE
in O
HBx _RARE_
- O
transfected O
HepG2 O
cells O
; O
and I-GENE
( O
iii O
) O
the I-GENE
inhibition O
of I-GENE
MEK I-GENE
activation O
by O
U0126 _RARE_
reduces O
Sp1 I-GENE
phosphorylation O
, O
P4 _RARE_
activity O
and I-GENE
IGF I-GENE
- O
II I-GENE
mRNA I-GENE
in O
HBx _RARE_
- O
transfected O
HepG2 O
cells O
. I-GENE

We O
show O
that O
p73 _RARE_
can O
transcriptionally O
inhibit O
a I-GENE
number O
of I-GENE
cellular I-GENE
and I-GENE
viral I-GENE
promoters O
. I-GENE

Similarly O
, O
curcumin _RARE_
( O
diferuloylmethane _RARE_
), O
an O
anti I-GENE
- O
inflammatory O
agent O
, O
suppressed O
OSM _RARE_
- O
stimulated O
STAT1 I-GENE
phosphorylation O
, O
DNA O
- O
binding I-GENE
activity O
of I-GENE
STAT1 I-GENE
, O
and I-GENE
c I-GENE
- O
Jun I-GENE
N I-GENE
- O
terminal O
kinase I-GENE
activation O
without O
affecting O
JAK1 _RARE_
, O
JAK2 _RARE_
, O
JAK3 _RARE_
, O
ERK1 I-GENE
/ O
2 I-GENE
, O
and I-GENE
p38 I-GENE
phosphorylation O
. I-GENE

The O
effects O
of I-GENE
the I-GENE
transfected O
receptors I-GENE
were O
associated I-GENE
with O
antagonism _RARE_
of I-GENE
activator O
protein I-GENE
1 I-GENE
( O
AP I-GENE
- O
1 I-GENE
) O
activity O
. I-GENE

Furthermore O
, O
the I-GENE
soluble O
forms O
of I-GENE
ATF6 _RARE_
and I-GENE
the I-GENE
G13 _RARE_
gene I-GENE
product I-GENE
are O
unable O
to O
bind O
to O
several O
point O
mutants I-GENE
of I-GENE
the I-GENE
cis O
- O
acting O
ER O
stress O
response O
element I-GENE
in O
vitro O
that O
hardly _RARE_
respond O
to O
ER O
stress O
in O
vivo O
. I-GENE

PURPOSE O
: I-GENE
The O
objective O
of I-GENE
this O
study O
was O
to O
assess O
first O
embryo O
cleavage O
( O
FEC _RARE_
) O
25 O
- O
27 _RARE_
h O
after O
intracytoplasmic _RARE_
sperm O
injection O
( O
ICSI _RARE_
) O
as _RARE_
a I-GENE
parameter O
for O
the I-GENE
embryo O
selection O
process O
. I-GENE

RESULTS O
: I-GENE
A I-GENE
significant O
correlation O
( O
p O
< O
0 O
. I-GENE
001 O
) O
was O
observed O
for O
mean O
wall O
thickness O
and I-GENE
vessel O
wall O
area O
between O
MRI O
and I-GENE
histopathology _RARE_
( O
r _RARE_
= O
0 O
. I-GENE
87 O
and I-GENE
r _RARE_
= O
0 O
. I-GENE
85 _RARE_
, O
respectively O
). O

Molecular O
cloning O
, O
genomic O
mapping O
, O
and I-GENE
expression _RARE_
of I-GENE
two O
secretor _RARE_
blood O
group O
alpha O
( O
1 I-GENE
, O
2 I-GENE
) O
fucosyltransferase _RARE_
genes I-GENE
differentially O
regulated O
in O
mouse I-GENE
uterine O
epithelium O
and I-GENE
gastrointestinal O
tract O
. I-GENE

We O
show O
that O
several O
heme O
- O
responsive I-GENE
mechanisms O
combine _RARE_
to O
regulate O
DAN _RARE_
/ O
TIR _RARE_
gene I-GENE
expression _RARE_
. I-GENE

No O
' I-GENE
TATA O
' I-GENE
motif O
was O
identified O
near O
either O
the I-GENE
GABPalpha _RARE_
or O
ATPsynCF6 _RARE_
transcription I-GENE
start O
sites I-GENE
. I-GENE

These O
results O
indicate O
the I-GENE
presence O
of I-GENE
TATA O
- O
unified _RARE_
transcription I-GENE
systems O
in O
contemporary _RARE_
eukaryotes O
and I-GENE
provide O
insight O
into O
the I-GENE
residual O
need O
for O
TBP I-GENE
by O
all O
three O
Pols _RARE_
in O
other O
eukaryotes O
despite O
a I-GENE
lack O
of I-GENE
TATA O
elements O
in O
their O
promoters O
. I-GENE

Different _RARE_
thermoluminescent _RARE_
detectors _RARE_
( O
TLD _RARE_
) O
have O
been O
used O
to O
measure O
the I-GENE
contribution O
of I-GENE
the I-GENE
low O
linear O
energy O
transfer O
component _RARE_
( O
LET _RARE_
< O
10 I-GENE
keV _RARE_
/ O
micrometer _RARE_
) O
and I-GENE
plastic _RARE_
nuclear O
track _RARE_
detectors _RARE_
( O
PNTD _RARE_
) O
for O
the I-GENE
high I-GENE
linear O
energy O
tranfer _RARE_
( O
LET _RARE_
) O
component _RARE_
. I-GENE

However O
, O
the I-GENE
beta5L _RARE_
splice O
variant I-GENE
was O
found O
only O
in O
the I-GENE
retina O
. I-GENE

This O
analysis O
supports O
the I-GENE
use O
of I-GENE
fluticasone _RARE_
propionate _RARE_
88 O
microg O
twice O
daily O
as _RARE_
first O
- O
line O
treatment O
in O
patients O
with O
persistent O
asthma O
previously O
treated O
with O
short O
- O
acting O
beta2 _RARE_
- O
agonist O
alone O
. I-GENE

The O
mice O
are O
phenotypically _RARE_
normal O
and I-GENE
do O
not O
develop O
spontaneous O
tumors O
at O
an O
early O
age O
, O
in O
contrast O
to O
knock _RARE_
- O
out O
( O
p53 I-GENE
(-/-)) _RARE_
strains O
with O
a I-GENE
defective O
p53 I-GENE
gene I-GENE
. I-GENE

Furthermore O
, O
stable O
expression _RARE_
of I-GENE
a I-GENE
constitutively O
active O
form O
of I-GENE
chicken I-GENE
Notch1 _RARE_
or O
Notch2 _RARE_
in O
a I-GENE
B I-GENE
cell I-GENE
line O
results O
in O
a I-GENE
down O
- O
regulation O
of I-GENE
surface O
IgM I-GENE
expression _RARE_
, O
which O
is O
accompanied O
by O
the I-GENE
reduction O
of I-GENE
IgH _RARE_
gene I-GENE
transcripts I-GENE
. I-GENE

On O
Cox O
proportional _RARE_
hazards _RARE_
regression O
adenocarcinoma O
( O
P I-GENE
= O
0 O
. I-GENE
006 _RARE_
), O
the I-GENE
development O
of I-GENE
BPF _RARE_
( O
P I-GENE
= O
0 O
. I-GENE
003 _RARE_
), O
older O
age O
( O
P I-GENE
= O
0 O
. I-GENE
03 O
) O
and I-GENE
higher O
pathological O
stage _RARE_
( O
P I-GENE
= O
0 O
. I-GENE
02 O
) O
were O
independent O
adverse O
predictors O
of I-GENE
survival O
. I-GENE

We O
found O
that O
RhoA I-GENE
can O
initiate O
a I-GENE
linear O
kinase I-GENE
cascade O
leading O
to O
the I-GENE
activation O
of I-GENE
ERK6 _RARE_
( O
p38 I-GENE
gamma I-GENE
), O
a I-GENE
recently O
identified O
member _RARE_
of I-GENE
the I-GENE
p38 I-GENE
family O
of I-GENE
MAPKs _RARE_
. I-GENE

Twenty O
- O
six O
( O
55 O
%) O
( O
95 _RARE_
% O
CI O
, O
41 _RARE_
- O
69 O
%) O
patients O
experienced O
> O
or O
= O
grade O
3 I-GENE
acute O
toxicity O
( O
RTOG _RARE_
). O

We O
hypothesize _RARE_
that O
proprioception _RARE_
may O
be O
used O
to O
calibrate _RARE_
the I-GENE
efference _RARE_
copy O
during O
development O
and I-GENE
in O
response O
to O
perturbations _RARE_
by O
signaling O
potential O
mismatches _RARE_
between O
eye O
movement O
information O
derived O
from I-GENE
the I-GENE
efferent _RARE_
command _RARE_
and I-GENE
the I-GENE
actual O
motion O
of I-GENE
the I-GENE
eye O
transduced _RARE_
by O
the I-GENE
proprioceptive _RARE_
organs O
. I-GENE

Thus O
, O
BALB O
/ O
c I-GENE
mice O
appear O
to O
be O
the I-GENE
most O
appropriate O
strain O
of I-GENE
mice O
to O
perform O
studies O
on O
the I-GENE
possible O
connection _RARE_
between O
infection O
with O
T I-GENE
. I-GENE
canis _RARE_
and I-GENE
allergic O
asthma O
. I-GENE

They O
correspond O
to O
nucleotides O
equivalent O
to O
base _RARE_
- O
pair O
C1 I-GENE
- O
G72 _RARE_
and I-GENE
discriminator _RARE_
base _RARE_
A73 _RARE_
in O
the I-GENE
amino I-GENE
acid O
- O
acceptor O
branch O
of I-GENE
the I-GENE
molecule I-GENE
. I-GENE

Our O
results O
suggest O
that O
the I-GENE
central O
role O
of I-GENE
the I-GENE
Notch I-GENE
- O
CBF1 I-GENE
/ O
RBP _RARE_
- O
Jkappa _RARE_
signaling O
pathway O
in O
cell I-GENE
fate O
decisions _RARE_
renders _RARE_
it O
susceptible O
to O
pathways O
of I-GENE
viral I-GENE
replication O
and I-GENE
oncogenic _RARE_
conversion O
. I-GENE

High O
- O
affinity O
binding I-GENE
of I-GENE
NF I-GENE
- O
1 I-GENE
to O
PSE _RARE_
- O
B I-GENE
, O
but O
not O
to O
PSE _RARE_
- O
A I-GENE
, O
was O
confirmed O
by O
competition O
of I-GENE
DNA O
- O
protein I-GENE
interactions O
by O
using O
NF I-GENE
- O
1 I-GENE
DNA O
elements O
and I-GENE
antibodies I-GENE
. I-GENE

The O
first O
case O
of I-GENE
HCV I-GENE
seroconversion _RARE_
in O
Portugal _RARE_
after O
the I-GENE
introduction O
of I-GENE
HCV I-GENE
NAT _RARE_
screening O
. I-GENE

Substitutions _RARE_
in O
the I-GENE
YFV _RARE_
Ag I-GENE
- O
binding I-GENE
region O
( O
ABR _RARE_
) O
occur O
at O
four O
of I-GENE
the I-GENE
eight O
highly O
conserved O
residues O
that O
are O
essential O
for O
binding I-GENE
of I-GENE
peptide I-GENE
- O
Ag I-GENE
in O
the I-GENE
class O
Ia _RARE_
molecules I-GENE
. I-GENE

The O
Novacor _RARE_
Left _RARE_
Ventricular _RARE_
Assist _RARE_
System _RARE_
( O
LVAS _RARE_
) O
( O
Novacor _RARE_
Corp _RARE_
, O
Oakland _RARE_
, O
CA I-GENE
) O
was O
initially O
console _RARE_
- O
based O
and I-GENE
has O
been O
available O
since O
1993 O
in O
a I-GENE
wearable _RARE_
configuration O
. I-GENE

Ileal _RARE_
digestibilities _RARE_
of I-GENE
DM O
, O
OM _RARE_
, O
CP O
, O
total O
dietary O
fiber O
( O
TDF _RARE_
), O
fat O
and I-GENE
gross O
energy O
( O
GE _RARE_
) O
were O
lower O
( O
P I-GENE
< O
0 O
. I-GENE
05 O
) O
for O
dogs O
fed O
diets O
containing O
supplemental _RARE_
fiber O
compared O
with O
dogs O
fed O
the I-GENE
control O
diet O
. I-GENE

In O
addition O
, O
the I-GENE
consensus I-GENE
amino I-GENE
acid O
motif O
for O
serine I-GENE
threonine I-GENE
receptor I-GENE
kinases I-GENE
was O
also O
present O
. I-GENE

Here O
, O
we O
show O
that O
the I-GENE
phorbol O
ester O
PMA O
decreases O
both O
basal I-GENE
and I-GENE
dexamethasone O
/ O
cAMP O
- O
induced O
expression _RARE_
of I-GENE
a I-GENE
luciferase I-GENE
gene I-GENE
under O
the I-GENE
control O
of I-GENE
the I-GENE
G6Pase _RARE_
promoter I-GENE
in O
transiently O
transfected O
H4IIE _RARE_
hepatoma O
cells O
. I-GENE

The O
difference O
between O
the I-GENE
patients O
and I-GENE
the I-GENE
controls O
was O
statistically O
significant O
( O
p O
= O
0 O
. I-GENE
03 O
). O

Altogether O
, O
we O
confirm O
that O
all O
genes I-GENE
of I-GENE
the I-GENE
Rad52 _RARE_
recombinational _RARE_
repair O
pathway O
are O
required O
for O
the I-GENE
survival O
of I-GENE
rad27 _RARE_
Delta O
strains O
at O
both O
permissive O
( O
23 O
degrees O
C I-GENE
) O
and I-GENE
semipermissive _RARE_
( O
30 _RARE_
degrees O
C I-GENE
) O
temperatures O
for O
growth I-GENE
. I-GENE

Neuron _RARE_
- O
specific I-GENE
Bcl I-GENE
- O
2 I-GENE
homology I-GENE
3 I-GENE
domain I-GENE
- O
only O
splice O
variant I-GENE
of I-GENE
Bak _RARE_
is O
anti I-GENE
- O
apoptotic O
in O
neurons O
, O
but O
pro I-GENE
- O
apoptotic O
in O
non O
- O
neuronal O
cells O
. I-GENE

The O
mechanism O
of I-GENE
the I-GENE
induction O
of I-GENE
3beta _RARE_
- O
HSD _RARE_
type I-GENE
1 I-GENE
gene I-GENE
expression _RARE_
was O
further O
characterized O
in O
ZR _RARE_
- O
75 O
- O
1 I-GENE
human O
breast O
cancer O
cells O
. I-GENE

Contagious _RARE_
bovine O
pleuropneumonia _RARE_
is O
a I-GENE
major I-GENE
threat _RARE_
for O
cattle O
in O
Africa _RARE_
. I-GENE

Treatment O
includes O
both O
medical O
and I-GENE
surgical O
options _RARE_
, O
with O
medical O
therapy O
further O
subclassified _RARE_
into O
pharmacologic _RARE_
and I-GENE
pneumatic _RARE_
dilation _RARE_
. I-GENE

Since O
the I-GENE
latter O
is O
very O
small I-GENE
for O
physiological O
flows _RARE_
, O
the I-GENE
result O
is O
that O
alpha O
< O
1 I-GENE
even O
at O
relatively O
high I-GENE
values O
of I-GENE
the I-GENE
Reynolds _RARE_
number O
( O
i I-GENE
. I-GENE
e _RARE_
., O
for O
non O
- O
negligible _RARE_
inertia _RARE_
) O
and I-GENE
we O
validate _RARE_
our O
perturbation _RARE_
theory O
results O
by O
comparison O
with O
a I-GENE
numerical _RARE_
integration O
of I-GENE
the I-GENE
full O
model O
. I-GENE

This O
plus _RARE_
the I-GENE
reduced O
phosphorylation O
of I-GENE
p27 I-GENE
by O
MAPK I-GENE
enhanced O
the I-GENE
stability O
of I-GENE
p27 I-GENE
that O
associated I-GENE
with O
nuclear O
Cdk2 I-GENE
at O
high I-GENE
stoichiometry _RARE_
and I-GENE
inhibited O
its O
kinase I-GENE
activity O
. I-GENE

Similar O
data O
were O
also O
obtained O
when O
either O
dominant I-GENE
negative O
EGFR I-GENE
- O
CD533 _RARE_
or O
dominant I-GENE
negative O
Ras I-GENE
N17 _RARE_
were O
used O
to O
block O
MAPK I-GENE
activation O
. I-GENE

The O
assay O
herein _RARE_
described O
allows O
the I-GENE
comparison O
of I-GENE
relative O
FGFR I-GENE
expression _RARE_
levels O
, O
both O
within O
a I-GENE
single I-GENE
RNA I-GENE
pool O
and I-GENE
among O
multiple O
RNA I-GENE
pool O
samples O
. I-GENE

This O
was O
most O
pronounced O
during O
the I-GENE
initial O
phase O
of I-GENE
Erk _RARE_
activation O
. I-GENE

DESIGN O
: I-GENE
Prospective _RARE_
cohort O
study O
with O
a I-GENE
20 O
y _RARE_
follow O
- O
up O
period O
, O
the I-GENE
First O
National O
Health O
and I-GENE
Examination O
Survey _RARE_
( O
NHANES _RARE_
1 I-GENE
) O
Epidemiologic _RARE_
Follow _RARE_
- O
up O
Study O
( O
NHEFS _RARE_
). O

To O
assess O
the I-GENE
maximum O
oxygen O
uptake O
( O
V O
' I-GENE
O2 O
max _RARE_
) O
of I-GENE
Hong _RARE_
Kong _RARE_
Chinese O
children O
and I-GENE
to O
explore O
its O
association O
with O
respiratory O
illnesses _RARE_
, O
we O
conducted O
the I-GENE
Multistage _RARE_
Fitness _RARE_
Test O
( O
MFT _RARE_
), O
a I-GENE
20 O
- O
m I-GENE
shuttle _RARE_
run O
test O
, O
in O
1 I-GENE
, O
427 _RARE_
schoolchildren _RARE_
aged O
between O
8 O
- O
12 O
years O
. I-GENE

After O
all O
doses O
of I-GENE
d I-GENE
- O
amphetamine O
, O
responding O
occurred O
largely O
on O
the I-GENE
saline O
key O
under O
both O
schedules _RARE_
. I-GENE

A I-GENE
novel O
myeloid _RARE_
- O
restricted O
zebrafish _RARE_
CCAAT I-GENE
/ O
enhancer I-GENE
- O
binding I-GENE
protein I-GENE
with O
a I-GENE
potent O
transcriptional O
activation O
domain I-GENE
. I-GENE

METHODS O
: I-GENE
Humphrey _RARE_
Field _RARE_
Analyzer _RARE_
model O
630 _RARE_
( O
HFA _RARE_
I I-GENE
, O
program O
30 _RARE_
- O
2 I-GENE
with O
a I-GENE
rectangular _RARE_
6 I-GENE
degrees O
x O
6 I-GENE
degrees O
grid _RARE_
) O
was O
used O
as _RARE_
the I-GENE
conventional O
perimetric _RARE_
method O
. I-GENE

These O
data O
reveal O
a I-GENE
complex I-GENE
network O
of I-GENE
interactions O
between O
GTPases I-GENE
in O
the I-GENE
ARF I-GENE
family O
and I-GENE
their O
effectors O
and I-GENE
reveal O
a I-GENE
potential O
for O
cross O
- O
talk _RARE_
not O
demonstrated O
previously O
. I-GENE

Net _RARE_
lift _RARE_
and I-GENE
combined O
drag _RARE_
from I-GENE
all O
8 O
bearings _RARE_
of I-GENE
the I-GENE
4 I-GENE
- O
bladed _RARE_
impeller _RARE_
are O
compared O
with O
predictions O
based O
on O
2 I-GENE
- O
D O
theory O
. I-GENE

In O
the I-GENE
course O
of I-GENE
screening O
for O
transcription I-GENE
factors O
which O
interact O
with O
the I-GENE
human O
myeloperoxidase _RARE_
( O
MPO _RARE_
) O
promoter I-GENE
we O
, O
for O
the I-GENE
first O
time O
, O
identified O
and I-GENE
cloned O
the I-GENE
cDNA O
and I-GENE
genomic O
DNA O
for O
human O
HBP1 _RARE_
( O
HMG I-GENE
- O
Box _RARE_
containing O
protein I-GENE
1 I-GENE
), O
a I-GENE
member _RARE_
of I-GENE
the I-GENE
high I-GENE
mobility O
group O
of I-GENE
non O
- O
histone I-GENE
chromosomal I-GENE
proteins I-GENE
. I-GENE

Therefore O
, O
vitamin O
D3 O
analogues O
have O
a I-GENE
substantial O
antipsoriatic _RARE_
effect O
. I-GENE

Methylation _RARE_
at O
both O
cytosine O
residues O
in O
the I-GENE
E2F I-GENE
element I-GENE
(( _RARE_
m I-GENE
) O
CG _RARE_
( O
m I-GENE
) O
CG _RARE_
) O
generated O
a I-GENE
new O
methylcytosine _RARE_
- O
specific I-GENE
DNA O
- O
protein I-GENE
complex I-GENE
. I-GENE

Hepatitis O
A I-GENE
infected O
food O
handler _RARE_
at O
an O
Edmonton _RARE_
, O
Alberta _RARE_
retail _RARE_
food O
facility _RARE_
: I-GENE
public _RARE_
health O
protection O
strategies O
. I-GENE

The O
co O
- O
existence O
of I-GENE
TE _RARE_
domains I-GENE
within O
modular _RARE_
PKSs _RARE_
along O
with O
physically O
separated O
, O
monofunctional _RARE_
TEs _RARE_
( O
TE _RARE_
IIs _RARE_
) O
has O
been O
reported O
for O
a I-GENE
number O
of I-GENE
modular _RARE_
polyketide _RARE_
and I-GENE
non O
- O
ribosomal I-GENE
peptide I-GENE
synthases _RARE_
( O
NRPS _RARE_
). O

Two O
independent O
transgenic O
lines O
were O
produced O
, O
and I-GENE
both O
showed O
expression _RARE_
of I-GENE
the I-GENE
Gus _RARE_
gene I-GENE
specifically O
in O
the I-GENE
endosperm _RARE_
during O
mid O
- O
development O
( O
first O
detected O
10 I-GENE
- O
12 O
d I-GENE
after O
anthesis _RARE_
). O

Treadmill _RARE_
training O
at O
least O
for O
2 I-GENE
weeks O
can O
reduce O
the I-GENE
infarction O
size O
and I-GENE
edema O
caused O
by O
MCA _RARE_
occlusion O
( O
P I-GENE
< O
0 O
. I-GENE
01 O
). O

Mechanism O
in O
the I-GENE
sequential O
control O
of I-GENE
cell I-GENE
morphology O
and I-GENE
S I-GENE
phase O
entry O
by O
epidermal _RARE_
growth I-GENE
factor O
involves O
distinct O
MEK I-GENE
/ O
ERK I-GENE
activations _RARE_
. I-GENE

We O
randomly O
assigned O
1 I-GENE
, O
219 _RARE_
subjects O
to O
receive O
either O
the I-GENE
standard O
three O
- O
times O
- O
weekly O
( O
TIW _RARE_
) O
interferon I-GENE
alfa _RARE_
- O
2b _RARE_
dose O
( O
3 I-GENE
MIU _RARE_
) O
or O
the I-GENE
once O
- O
weekly O
( O
QW _RARE_
) O
peginterferon _RARE_
alfa _RARE_
- O
2b _RARE_
( O
0 O
. I-GENE
5 O
, O
1 I-GENE
. I-GENE
0 O
, O
or O
1 I-GENE
. I-GENE
5 O
microg O
/ O
kg O
). O

These O
data O
suggest O
that O
proper O
direct O
binding I-GENE
of I-GENE
Nhp2p _RARE_
to O
H I-GENE
/ O
ACA _RARE_
snoRNAs _RARE_
is O
required O
for O
the I-GENE
assembly O
of I-GENE
H I-GENE
/ O
ACA _RARE_
snoRNPs _RARE_
and I-GENE
hence O
for O
the I-GENE
stability O
of I-GENE
some O
of I-GENE
their O
components _RARE_
. I-GENE

The O
decrements _RARE_
in O
cerebrovascular _RARE_
resistance O
induced O
by O
hexamethonium _RARE_
, O
in O
mm O
Hg O
ml O
(- O
1 I-GENE
). O
min O
(- O
1 I-GENE
), O
were O
: I-GENE
under O
control O
. I-GENE

Here O
we O
provide O
the I-GENE
first O
evidence O
for O
the I-GENE
involvement O
of I-GENE
GCN1 _RARE_
- O
GCN2 I-GENE
interaction I-GENE
in O
activation O
of I-GENE
GCN2 I-GENE
per O
se _RARE_
. I-GENE

As O
a I-GENE
reflection _RARE_
of I-GENE
uncertainties _RARE_
in O
the I-GENE
estimates O
for O
individual O
sources O
, O
the I-GENE
90th _RARE_
percentiles _RARE_
of I-GENE
PCDD _RARE_
/ O
F I-GENE
releases _RARE_
for O
1999 _RARE_
ranged O
up O
to O
4 I-GENE
. I-GENE
1 I-GENE
g O
I I-GENE
- O
TEQ _RARE_
/ O
y _RARE_
. I-GENE

To O
test O
the I-GENE
hypothesis O
that O
these O
elements O
are O
required O
for O
promoter I-GENE
activity O
, O
we O
compared O
the I-GENE
reporter I-GENE
expression _RARE_
activity O
of I-GENE
segments O
containing O
mutations O
of I-GENE
these O
elements O
with O
activity O
of I-GENE
the I-GENE
parent _RARE_
Hlx _RARE_
promoter I-GENE
sequence I-GENE
. I-GENE

Using O
RACE O
techniques O
we O
have O
cloned O
and I-GENE
sequenced O
one O
of I-GENE
the I-GENE
hamster O
liver O
3 I-GENE
- O
hydroxy O
- O
hexobarbital _RARE_
dehydrogenases _RARE_
which O
catalyze _RARE_
not O
only O
cyclic I-GENE
alcohols _RARE_
but O
also O
17beta _RARE_
- O
hydroxy O
- O
steroids O
and I-GENE
3alpha _RARE_
- O
hydroxysteroids _RARE_
. I-GENE

Concerted _RARE_
transcriptional O
activation O
of I-GENE
the I-GENE
low O
density O
lipoprotein I-GENE
receptor I-GENE
gene I-GENE
by O
insulin I-GENE
and I-GENE
luteinizing _RARE_
hormone I-GENE
in O
cultured O
porcine _RARE_
granulosa _RARE_
- O
luteal O
cells O
: I-GENE
possible O
convergence _RARE_
of I-GENE
protein I-GENE
kinase I-GENE
a I-GENE
, O
phosphatidylinositol _RARE_
3 I-GENE
- O
kinase I-GENE
, O
and I-GENE
mitogen I-GENE
- O
activated I-GENE
protein I-GENE
kinase I-GENE
signaling O
pathways O
. I-GENE

Human I-GENE
T I-GENE
- O
cell I-GENE
leukemia O
virus I-GENE
type I-GENE
I I-GENE
( O
HTLV _RARE_
- O
I I-GENE
) O
Tax I-GENE
is O
a I-GENE
potent O
transcriptional O
regulator O
that O
can O
activate O
or O
repress O
specific I-GENE
cellular I-GENE
genes I-GENE
and I-GENE
that O
has O
been O
proposed O
to O
contribute O
to O
leukemogenesis _RARE_
in O
adult O
T I-GENE
- O
cell I-GENE
leukemia O
. I-GENE

Also O
, O
small I-GENE
, O
sense O
and I-GENE
antisense O
approximately O
22 O
nt O
RNAs I-GENE
, O
derived O
from I-GENE
the I-GENE
satRNA _RARE_
, O
were O
associated I-GENE
with O
the I-GENE
replicating O
satellite O
. I-GENE

Deletional _RARE_
analyses O
of I-GENE
VDR I-GENE
indicated O
that O
GRIP1 _RARE_
and I-GENE
RAC3 _RARE_
required O
an O
intact O
VDR I-GENE
activation O
function O
( O
AF _RARE_
- O
2 I-GENE
) O
domain I-GENE
for O
efficient O
interaction I-GENE
as _RARE_
well _RARE_
as _RARE_
additional O
but O
distinct O
regions O
of I-GENE
the I-GENE
VDR I-GENE
. I-GENE

RESULTS O
: I-GENE
During O
the I-GENE
stabilization O
period O
, O
PaCO2 O
( O
mean O
+/- O
SD O
) O
was O
33 O
+/- O
5 O
mm O
Hg O
, O
and I-GENE
arrhythmias O
were O
not O
detected O
. I-GENE

TT _RARE_
cells O
, O
a I-GENE
human O
MTC _RARE_
cell I-GENE
line O
expressing O
MEN _RARE_
2A _RARE_
type I-GENE
RET I-GENE
, O
display O
transcriptionally O
active O
RelA _RARE_
( O
p65 I-GENE
) O
in O
the I-GENE
nucleus O
. I-GENE

The O
human O
protein I-GENE
sequence I-GENE
exhibits O
a I-GENE
putative O
DNA O
- O
binding I-GENE
domain I-GENE
similar O
to O
that O
seen O
in O
rat O
HBP1 _RARE_
and I-GENE
shows O
homology I-GENE
with O
the I-GENE
activation O
and I-GENE
repressor O
domains I-GENE
previously O
demonstrated O
in O
the I-GENE
rat O
protein I-GENE
. I-GENE

In O
contrast O
the I-GENE
human O
and I-GENE
mouse I-GENE
BCNT _RARE_
proteins I-GENE
contain O
one O
repeat I-GENE
unit I-GENE
and I-GENE
lack O
the I-GENE
RTE _RARE_
- O
1 I-GENE
- O
derived O
portion O
. I-GENE

Direct _RARE_
superoxide I-GENE
scavenging _RARE_
activity O
of I-GENE
nonsteroidal _RARE_
anti I-GENE
- O
inflammatory O
drugs O
: I-GENE
determination O
by O
electron O
spin O
resonance O
using O
the I-GENE
spin O
trap _RARE_
method O
. I-GENE

A I-GENE
single I-GENE
nucleotide O
polymorphism O
( O
SNP _RARE_
) O
in O
exon O
2 I-GENE
, O
which O
is O
tightly O
liked _RARE_
to O
another O
SNP _RARE_
( O
GTG83 _RARE_
/ O
ATG83 _RARE_
), O
creates _RARE_
an O
additional O
alternative O
in O
- O
frame O
AUG O
in O
B I-GENE
- O
type I-GENE
MTH1 _RARE_
mRNAs O
yielding _RARE_
the I-GENE
fourth O
MTH1 _RARE_
polypeptide I-GENE
, O
p26 _RARE_
that O
possesses O
an O
additional O
mitochondrial I-GENE
targeting O
signal O
. I-GENE

Six O
of I-GENE
the I-GENE
gstC _RARE_
' I-GENE
mutants I-GENE
, O
primarily O
in O
the I-GENE
C I-GENE
- O
terminal O
half O
of I-GENE
C I-GENE
', O
exhibited O
a I-GENE
defect O
in O
the I-GENE
ability O
to O
bind O
L I-GENE
protein I-GENE
. I-GENE

We O
developed O
a I-GENE
system O
for O
domain I-GENE
shuffling _RARE_
to O
establish O
the I-GENE
function O
of I-GENE
C1 I-GENE
domains I-GENE
from I-GENE
human O
Raf I-GENE
kinase I-GENE
and I-GENE
rat O
PKC I-GENE
eta _RARE_
in O
yeast O
. I-GENE

Expression O
of I-GENE
herpes O
simplex I-GENE
virus I-GENE
type I-GENE
2 I-GENE
US3 _RARE_
affects O
the I-GENE
Cdc42 I-GENE
/ O
Rac I-GENE
pathway O
and I-GENE
attenuates O
c I-GENE
- O
Jun I-GENE
N I-GENE
- O
terminal O
kinase I-GENE
activation O
. I-GENE

Inhibition O
of I-GENE
constitutive O
NF I-GENE
- O
kappaB I-GENE
activity O
results O
in O
cell I-GENE
death _RARE_
of I-GENE
TT _RARE_
cells O
and I-GENE
blocks O
focus O
formation O
induced O
by O
oncogenic _RARE_
forms O
of I-GENE
RET I-GENE
in O
NIH O
3T3 O
cells O
. I-GENE

Corneal _RARE_
scrapping _RARE_
and I-GENE
deep O
stromal _RARE_
biopsy O
were O
obtained O
and I-GENE
stained O
for O
microscopic O
evaluation O
with O
periodic O
acid O
- O
Schiff _RARE_
, O
Giemsa _RARE_
, O
and I-GENE
Gomori _RARE_
' I-GENE
s I-GENE
methenamine _RARE_
silver O
stains _RARE_
. I-GENE

ICAM _RARE_
- O
1 I-GENE
has O
been O
suggested O
a I-GENE
predictor O
of I-GENE
the I-GENE
onset O
of I-GENE
GO _RARE_
. I-GENE

Once O
ICP _RARE_
reaches _RARE_
critical O
values O
(> O
30 _RARE_
mm O
Hg O
) O
herniation _RARE_
occurs O
, O
usually O
within O
2 I-GENE
to O
5 O
days O
. I-GENE

The O
present O
data O
also O
demonstrate O
that O
ectopic O
expression _RARE_
of I-GENE
blr1 _RARE_
increased O
JNK I-GENE
/ O
SAPK I-GENE
activity O
, O
but O
JNK I-GENE
/ O
SAPK I-GENE
activation O
was O
not O
needed O
for O
accelerated O
RA O
- O
induced O
differentiation O
and I-GENE
growth I-GENE
arrest O
. I-GENE

Here O
, O
we O
identify O
Rsc3 _RARE_
and I-GENE
Rsc30 _RARE_
as _RARE_
novel O
components _RARE_
of I-GENE
the I-GENE
essential O
yeast O
remodeler _RARE_
RSC _RARE_
complex I-GENE
. I-GENE

The O
pharmacokinetic O
profiles O
of I-GENE
digoxin _RARE_
and I-GENE
warfarin _RARE_
were O
not O
altered O
by O
the I-GENE
simultaneous O
and I-GENE
continued O
administration O
of I-GENE
sevelamer _RARE_
. I-GENE

Forskolin _RARE_
treatment O
( O
10 I-GENE
microM O
) O
of I-GENE
the I-GENE
transfected O
cells O
for O
3 I-GENE
-- O
6 I-GENE
h O
maximally _RARE_
induced O
luciferase I-GENE
threefold O
. I-GENE

E2F1 I-GENE
- O
mediated O
transcriptional O
inhibition O
of I-GENE
the I-GENE
plasminogen I-GENE
activator O
inhibitor I-GENE
type I-GENE
1 I-GENE
gene I-GENE
. I-GENE

In O
this O
report O
this O
technique O
was O
applied O
to O
human O
breast O
carcinoma O
MDA _RARE_
- O
MB231 _RARE_
cells O
overexpressing O
human O
MPG _RARE_
in O
order O
to O
assess O
whether O
up O
- O
regulation O
of I-GENE
the I-GENE
initial O
step O
in O
BER _RARE_
alters O
the I-GENE
activity O
of I-GENE
selected O
other O
BER _RARE_
( O
hOGG1 _RARE_
and I-GENE
APE _RARE_
/ O
ref _RARE_
- O
1 I-GENE
) O
or O
direct O
reversal O
( O
MGMT _RARE_
) O
repair O
activities O
. I-GENE

Chlamydia O
and I-GENE
cervical O
cancer O
: I-GENE
a I-GENE
real O
association O
? O

In O
children O
unable O
to O
perform O
forced _RARE_
expiratory O
maneuvers _RARE_
( O
n O
= O
25 O
), O
FOT _RARE_
, O
contrary _RARE_
to O
the I-GENE
interrupter _RARE_
technique O
, O
clearly O
identified O
a I-GENE
subgroup O
of I-GENE
young O
children O
with O
high I-GENE
resistance O
values O
at O
baseline O
, O
which O
returned O
to O
normal O
after O
bronchodilation _RARE_
. I-GENE

Together O
, O
these O
results O
identify O
HPK1 _RARE_
as _RARE_
a I-GENE
new O
component _RARE_
of I-GENE
TCR I-GENE
signaling O
. I-GENE

Pro _RARE_
- O
inflammatory O
cytokine O
, O
tumor O
necrosis I-GENE
factor O
- O
alpha O
( O
TNF I-GENE
- O
alpha O
), O
produced O
from I-GENE
adipose O
tissues O
in O
obese O
subjects O
, O
is O
known O
to O
play O
a I-GENE
predominant O
role O
in O
inducing O
insulin I-GENE
resistance O
. I-GENE

The O
Schistosoma _RARE_
mansoni _RARE_
homologue O
( O
SmSmad2 _RARE_
) O
was O
overexpressed O
in O
bacteria O
as _RARE_
a I-GENE
Sj26 _RARE_
- O
GST I-GENE
fusion O
protein I-GENE
and I-GENE
used O
to O
raise _RARE_
specific I-GENE
antibodies I-GENE
. I-GENE

To O
study O
the I-GENE
in O
vivo O
role O
of I-GENE
p16 I-GENE
. I-GENE
7 I-GENE
, O
a I-GENE
phi29 _RARE_
mutant I-GENE
containing O
a I-GENE
suppressible _RARE_
mutation I-GENE
in O
gene I-GENE
16 O
. I-GENE
7 I-GENE
was O
constructed O
. I-GENE

The O
differences O
in O
the I-GENE
CPIgG _RARE_
, O
CRP I-GENE
, O
and I-GENE
fibrinogen I-GENE
levels O
in O
patients O
who O
were O
diagnosed O
with O
ACS _RARE_
versus O
those O
who O
were O
not O
( O
non O
- O
ACS _RARE_
) O
were O
evaluated O
. I-GENE

There O
are O
many O
different O
proposals _RARE_
for O
the I-GENE
statistical O
analysis O
of I-GENE
data O
to O
determine O
early O
onset O
of I-GENE
action O
. I-GENE

Coexpression _RARE_
of I-GENE
the I-GENE
p120 _RARE_
( O
ctn _RARE_
) O
protein I-GENE
with O
an O
N I-GENE
- O
terminal O
deletion O
, O
which O
eliminates _RARE_
some O
potential O
tyrosine I-GENE
phosphorylation O
sites I-GENE
, O
or O
the I-GENE
protein I-GENE
with O
a I-GENE
single I-GENE
amino I-GENE
acid O
substitution O
( O
tyrosine I-GENE
at O
217 _RARE_
to O
phenylalanine _RARE_
) O
resulted O
in O
an O
increase O
in O
the I-GENE
aggregation _RARE_
of I-GENE
v I-GENE
- O
Src I-GENE
- O
transformed O
EL _RARE_
and I-GENE
EalphaCL _RARE_
cells O
. I-GENE

We O
find O
that O
our O
response O
function O
is O
well _RARE_
approximated _RARE_
by O
the I-GENE
GSER _RARE_
only O
within O
a I-GENE
particular O
frequency O
range O
determined O
by O
the I-GENE
material O
parameters O
of I-GENE
both O
the I-GENE
bead _RARE_
and I-GENE
the I-GENE
network O
. I-GENE

The O
novel O
approach O
to O
insulin I-GENE
administration O
known O
as _RARE_
chronic O
intermittent O
intravenous O
insulin I-GENE
therapy O
( O
CIIIT _RARE_
) O
delivers _RARE_
insulin I-GENE
in O
a I-GENE
pulsatile _RARE_
fashion O
and I-GENE
achieves _RARE_
physiological O
insulin I-GENE
concentration O
in O
the I-GENE
portal _RARE_
vein O
. I-GENE

This O
article O
comparatively _RARE_
evaluates _RARE_
five O
Generic _RARE_
Systems _RARE_
that O
describe O
the I-GENE
basic I-GENE
alternatives _RARE_
to O
composting _RARE_
facility _RARE_
design O
and I-GENE
control O
. I-GENE

With O
a I-GENE
GC O
content O
of I-GENE
45 O
% O
the I-GENE
one O
segment I-GENE
would O
correspond O
to O
" I-GENE
isochore _RARE_
H1 I-GENE
" I-GENE
and I-GENE
the I-GENE
other O
segment I-GENE
( O
39 _RARE_
% O
GC O
in O
human O
, O
40 I-GENE
% O
GC O
in O
mouse I-GENE
) O
to O
" I-GENE
isochore _RARE_
L1 I-GENE
/ O
L2 O
". O

A I-GENE
review O
of I-GENE
the I-GENE
literature O
identified O
8 O
comprehensive _RARE_
clinical O
studies O
, O
all O
of I-GENE
which O
failed O
to O
document _RARE_
any O
relationship O
between O
NF1 I-GENE
and I-GENE
intracranial _RARE_
aneurysms _RARE_
. I-GENE

Serial _RARE_
US O
images O
were O
obtained O
before O
and I-GENE
20 O
, O
30 _RARE_
, O
40 I-GENE
, O
50 O
, O
60 _RARE_
, O
90 O
, O
120 O
, O
150 O
, O
180 O
, O
240 O
, O
and I-GENE
300 O
s I-GENE
after O
intravenous O
injection O
of I-GENE
2 I-GENE
g O
of I-GENE
contrast O
agent O
using O
conventional O
and I-GENE
harmonic _RARE_
PD _RARE_
US O
. I-GENE

Eight O
CAD I-GENE
patients O
who O
were O
matched O
to O
the I-GENE
treated O
patients O
for O
age O
(+/- O
3 I-GENE
years O
), O
baseline O
low O
density O
lipoprotein I-GENE
(+/- O
5 O
mg O
/ O
dL O
), O
and I-GENE
triglycerides _RARE_
(+/- O
50 O
mg O
/ O
dL O
) O
but O
who O
had O
never O
been O
treated O
with O
lipid O
- O
lowering O
drugs O
were O
selected O
as _RARE_
controls O
. I-GENE

Here O
we O
present O
evidence O
that O
the I-GENE
distal O
half O
( O
Stem _RARE_
2 I-GENE
) O
of I-GENE
the I-GENE
conserved O
base _RARE_
- O
paired I-GENE
stem O
structure O
found O
in O
all O
hY _RARE_
RNAs I-GENE
also O
plays O
a I-GENE
critical O
role O
in O
the I-GENE
export O
process O
. I-GENE

The O
contrasting _RARE_
effects O
of I-GENE
dopaminergic O
stimulation O
on O
the I-GENE
motor O
performance O
and I-GENE
on O
some O
aspects O
of I-GENE
cognitive O
processing O
suggest O
the I-GENE
existence O
of I-GENE
complex I-GENE
interactions O
within O
pre I-GENE
- O
and I-GENE
postsynaptic _RARE_
brain I-GENE
dopamine I-GENE
receptors I-GENE
, O
and I-GENE
an O
intervention O
of I-GENE
segregated _RARE_
basal I-GENE
ganglia _RARE_
- O
prefrontal _RARE_
cortex O
loops O
in O
motor O
and I-GENE
cognitive O
behaviour O
. I-GENE

The O
size O
of I-GENE
the I-GENE
infarct O
was O
determined O
using O
the I-GENE
creatine I-GENE
kinase I-GENE
integral _RARE_
method O
. I-GENE

These O
corrections _RARE_
do O
not O
involve O
sequences O
predicted O
to O
function O
as _RARE_
transcription I-GENE
factor O
binding I-GENE
sites I-GENE
. I-GENE

A I-GENE
comprehensive _RARE_
neuropsychological _RARE_
battery O
was O
administered O
to O
48 O
veterans _RARE_
with O
Gulf _RARE_
War _RARE_
Illness _RARE_
( O
GWI _RARE_
) O
characterized O
by O
severe O
fatigue _RARE_
( O
GV _RARE_
- O
F I-GENE
) O
and I-GENE
39 _RARE_
healthy O
veterans _RARE_
( O
GV _RARE_
- O
H I-GENE
). O

Quantitative O
PCR O
studies O
indicated O
that O
synthesis _RARE_
and I-GENE
transport O
of I-GENE
vector O
DNA O
into O
the I-GENE
nucleus O
were O
similar O
for O
macrophages O
infected O
with O
the I-GENE
clone O
239 O
and I-GENE
316 _RARE_
pseudotypes _RARE_
, O
suggesting O
that O
the I-GENE
restriction O
for O
SIVmac239 _RARE_
infection O
is O
after O
reverse I-GENE
transcription I-GENE
and I-GENE
nuclear O
import O
of I-GENE
viral I-GENE
DNA O
. I-GENE

EXAFS _RARE_
measurements O
around O
the I-GENE
Ge _RARE_
- O
K I-GENE
edge _RARE_
have O
been O
carried O
out O
for O
liquid O
Ge _RARE_
- O
Si _RARE_
alloys _RARE_
for O
the I-GENE
first O
time O
to O
investigate O
the I-GENE
local O
structure O
around O
a I-GENE
Ge _RARE_
atom _RARE_
. I-GENE

Hp _RARE_
positive O
relatives _RARE_
of I-GENE
gastric O
cancer O
had O
a I-GENE
markedly O
higher O
prevalence O
of I-GENE
atrophy O
than O
those O
with O
Hp _RARE_
negativity _RARE_
without O
cancer O
relatives _RARE_
( O
29 O
vs O
. I-GENE

Thus O
, O
replication O
fork I-GENE
movement O
near O
HML _RARE_
pauses _RARE_
at O
a I-GENE
silent _RARE_
origin O
which O
is O
competent O
for O
replication O
initiation O
but O
kept O
silent _RARE_
through O
Orc2p _RARE_
, O
a I-GENE
component _RARE_
of I-GENE
the I-GENE
replication O
initiator O
. I-GENE

Cardiac O
markers O
troponin _RARE_
T I-GENE
, O
CK _RARE_
- O
MB O
mass O
and I-GENE
myoglobin I-GENE
were O
helpful O
in O
the I-GENE
differential O
diagnosis O
of I-GENE
chest O
pain O
, O
even O
when O
the I-GENE
ECG O
was O
unremarkable _RARE_
or O
nonspecific O
. I-GENE

RESULTS O
: I-GENE
A I-GENE
novel O
gene I-GENE
was O
cloned O
. I-GENE

Both O
pancreatic O
and I-GENE
intestinal _RARE_
cell I-GENE
lines O
were O
found O
to O
express O
a I-GENE
number O
of I-GENE
POU I-GENE
( O
OCT _RARE_
binding I-GENE
) O
homeodomain I-GENE
proteins I-GENE
examined O
by O
electrophoretic O
mobility O
shift O
assay O
. I-GENE

In O
conclusion O
, O
USPIO _RARE_
- O
enhanced O
MRI O
data O
were O
capable O
to O
characterize O
tumor O
microvessel _RARE_
properties O
in O
this O
breast O
cancer O
model O
: I-GENE
microvascular O
permeability O
( O
determined O
using O
USPIO _RARE_
) O
correlated O
significantly O
with O
tumor O
grade O
. I-GENE

Radiolabeled _RARE_
biantennary _RARE_
N I-GENE
- O
glycans _RARE_
synthesized O
by O
Pro _RARE_
(-) _RARE_
5Lec20 _RARE_
were O
proportionately _RARE_
less O
ricin _RARE_
- O
bound O
than O
similar O
species O
from I-GENE
parental O
CHO O
cells O
, O
and I-GENE
Lec20 _RARE_
cell I-GENE
extracts O
had O
a I-GENE
markedly O
reduced O
ability O
to O
transfer O
Gal _RARE_
to O
GlcNAc _RARE_
- O
terminating _RARE_
acceptors _RARE_
. I-GENE

CONCLUSION O
: I-GENE
The O
training O
of I-GENE
novices _RARE_
using O
MIST _RARE_
- O
VR _RARE_
yields O
quantifiable _RARE_
changes O
in O
skill _RARE_
that O
are O
transferable _RARE_
to O
a I-GENE
simple O
real O
task O
and I-GENE
are O
similar O
to O
the I-GENE
results O
achieved O
with O
conventional O
training O
. I-GENE

To O
investigate O
the I-GENE
convergent _RARE_
role O
of I-GENE
the I-GENE
insulin I-GENE
/ O
IGF I-GENE
- O
I I-GENE
effector O
pathway O
mediating O
bihormonal _RARE_
stimulation O
of I-GENE
LDL I-GENE
receptor I-GENE
promoter I-GENE
expression _RARE_
, O
transfected O
granulosa _RARE_
- O
luteal O
cells O
were O
pretreated O
for O
30 _RARE_
min O
with O
two O
specific I-GENE
inhibitors O
of I-GENE
phophatidylinositol _RARE_
3 I-GENE
- O
kinase I-GENE
, O
wortmannin O
( O
100 O
nM O
) O
and I-GENE
LY _RARE_
294002 _RARE_
( O
10 I-GENE
microM O
), O
or O
of I-GENE
mitogen I-GENE
- O
activated I-GENE
protein I-GENE
kinase I-GENE
kinase I-GENE
, O
PD _RARE_
98059 _RARE_
( O
50 O
microM O
), O
U0126 _RARE_
( O
10 I-GENE
microM O
), O
or O
the I-GENE
latter O
' I-GENE
s I-GENE
inactive O
derivative O
, O
U0124 _RARE_
( O
10 I-GENE
microM O
). O

Instead O
, O
affective O
flattening _RARE_
was O
associated I-GENE
with O
both O
dopamine I-GENE
receptor I-GENE
sensitivity O
and I-GENE
psychomotor _RARE_
slowing _RARE_
. I-GENE

Other O
therapies _RARE_
are O
also O
available O
, O
including O
hypertonic _RARE_
saline O
solution O
, O
THAM _RARE_
( O
Tris _RARE_
- O
hydroxy O
- O
methyl O
- O
aminomethane _RARE_
) O
buffer _RARE_
, O
and I-GENE
high I-GENE
- O
dose O
barbiturates _RARE_
. I-GENE

CONCLUSION O
: I-GENE
There O
are O
no O
differences O
in O
the I-GENE
measurement O
data O
derived O
from I-GENE
this O
method O
and I-GENE
actual O
measurement O
data O
from I-GENE
an O
object _RARE_
created O
by O
the I-GENE
computer O
- O
aided _RARE_
dental O
design O
program O
. I-GENE

NF I-GENE
- O
kappaB I-GENE
pathway O
activation O
occurs O
during O
transformation O
induced O
by O
a I-GENE
number O
of I-GENE
classical O
oncogenes O
, O
including O
Bcr _RARE_
/ O
Abl I-GENE
, O
Ras I-GENE
and I-GENE
Rac I-GENE
, O
and I-GENE
is O
necessary O
for O
full O
transforming O
potential O
. I-GENE

Our O
results O
indicate O
that O
Gab1 _RARE_
is O
involved O
in O
the I-GENE
control O
of I-GENE
egr _RARE_
- O
1 I-GENE
expression _RARE_
regulated O
by O
insulin I-GENE
. I-GENE

The O
human O
cytomegalovirus _RARE_
( O
HCMV _RARE_
) O
major I-GENE
immediate I-GENE
- O
early O
protein I-GENE
IE2 I-GENE
is O
a I-GENE
nuclear O
phosphoprotein O
that O
is O
believed O
to O
be O
a I-GENE
key O
regulator O
in O
both O
lytic O
and I-GENE
latent I-GENE
infections O
. I-GENE

Unexpectedly _RARE_
, O
Arg1 _RARE_
- O
expressing O
COS1 _RARE_
cells O
showed O
no O
significant O
proteinase I-GENE
activity O
to O
various O
synthesized O
substrates O
under O
neutral O
or O
acidic O
conditions O
in O
this O
study O
. I-GENE

METHODS O
: I-GENE
126 O
patients O
with O
histologically O
confirmed O
MFH _RARE_
were O
analyzed O
. I-GENE

Regression _RARE_
analyses O
showed O
that O
SOREMP _RARE_
dream _RARE_
occurrences _RARE_
were O
significantly O
related I-GENE
to O
the I-GENE
amount O
of I-GENE
REM O
sleep O
, O
while O
NREMP _RARE_
dream _RARE_
occurrences _RARE_
were O
related I-GENE
to O
arousals _RARE_
from I-GENE
NREM _RARE_
sleep O
. I-GENE

[ _RARE_
Diabetologia _RARE_
( O
2001 _RARE_
) O
44 _RARE_
[ _RARE_
Suppl _RARE_
3 I-GENE
]: _RARE_
B37 _RARE_
- O
B44 _RARE_
] O

RESULTS O
: I-GENE
In O
vivo O
, O
there O
was O
a I-GENE
wide O
distribution O
with O
the I-GENE
coefficient O
of I-GENE
variation O
( O
SD O
/ O
mean O
x O
100 O
%) O
for O
different O
valve O
sizes O
ranging O
from I-GENE
21 O
% O
to O
39 _RARE_
% O
in O
the I-GENE
St _RARE_
Jude _RARE_
Medical _RARE_
valve O
and I-GENE
from I-GENE
25 O
% O
to O
33 O
% O
in O
the I-GENE
Omnicarbon _RARE_
valve O
. I-GENE

A I-GENE
microsporidian _RARE_
, O
Nosema _RARE_
algerae _RARE_
Vavra _RARE_
and I-GENE
undeen _RARE_
, O
was O
found O
parasitizing _RARE_
larvae O
and I-GENE
adults O
of I-GENE
a I-GENE
laboratory O
colony I-GENE
of I-GENE
Culex _RARE_
pipiens _RARE_
L I-GENE
. I-GENE
originated _RARE_
from I-GENE
Gharbia _RARE_
Governorate _RARE_
. I-GENE

Nearly _RARE_
all O
isolates O
of I-GENE
S I-GENE
. I-GENE
intermedius _RARE_
and I-GENE
most O
isolates O
of I-GENE
S I-GENE
. I-GENE
constellatus _RARE_
, O
but O
only O
19 I-GENE
% O
of I-GENE
those O
of I-GENE
S I-GENE
. I-GENE
anginosus _RARE_
, O
were O
associated I-GENE
with O
abscess O
. I-GENE

One O
of I-GENE
the I-GENE
conserved O
RNA I-GENE
subdomains O
, O
designated O
P3 O
, O
has O
previously O
been O
shown O
to O
be O
required O
for O
nucleolar _RARE_
localization O
. I-GENE

A I-GENE
total O
of I-GENE
25 O
patients O
with O
malignant O
brain I-GENE
tumours O
were O
investigated O
. I-GENE

Interventions _RARE_
aimed O
at O
these O
specific I-GENE
mediators _RARE_
and I-GENE
processes O
may O
be O
successful O
in O
reducing O
the I-GENE
very O
significant O
human O
and I-GENE
economic _RARE_
costs O
of I-GENE
vascular I-GENE
access O
dysfunction O
. I-GENE

We O
used O
stored O
plasma I-GENE
samples O
from I-GENE
409 _RARE_
patients O
in O
the I-GENE
National O
Institute O
of I-GENE
Neurological _RARE_
Diseases _RARE_
and I-GENE
Stroke _RARE_
( O
NINDS _RARE_
) O
tissue I-GENE
plasminogen I-GENE
activator O
( O
t O
- O
PA I-GENE
) O
Stroke _RARE_
Trial _RARE_
to O
examine O
the I-GENE
relationship O
between O
an O
apolipoprotein I-GENE
( O
Apo _RARE_
) O
E2 I-GENE
or O
an O
Apo _RARE_
E4 _RARE_
phenotype O
and I-GENE
a I-GENE
favorable _RARE_
outcome O
3 I-GENE
months O
after O
stroke O
, O
the I-GENE
risk O
of I-GENE
intracerebral _RARE_
hemorrhage O
, O
and I-GENE
the I-GENE
response O
to O
intravenous O
t O
- O
PA I-GENE
therapy O
. I-GENE

These O
results O
were O
robust _RARE_
to O
changes O
in O
the I-GENE
baseline O
assumptions _RARE_
of I-GENE
the I-GENE
model O
. I-GENE

Cis _RARE_
- O
acting O
CCAAT I-GENE
elements O
are O
frequently O
found O
in O
eukaryotic O
promoter I-GENE
regions O
. I-GENE

The O
binary _RARE_
and I-GENE
tertiary O
combinations O
of I-GENE
plant _RARE_
- O
derived O
molluscicides _RARE_
Azadirachta _RARE_
indica _RARE_
and I-GENE
Cedrus _RARE_
deodara _RARE_
oil O
with O
synergists _RARE_
MGK _RARE_
- O
264 O
, O
piperonyl _RARE_
butoxide _RARE_
( O
PB _RARE_
) O
and I-GENE
fruit _RARE_
powder _RARE_
of I-GENE
Embelia _RARE_
ribes _RARE_
were O
used O
against O
the I-GENE
Lymnaea _RARE_
acuminata _RARE_
. I-GENE

This O
article O
reports O
the I-GENE
design O
and I-GENE
development O
of I-GENE
an O
ECG O
simulator _RARE_
intended _RARE_
for O
use O
in O
the I-GENE
testing O
, O
calibration _RARE_
and I-GENE
maintenance O
of I-GENE
electrocardiographic _RARE_
equipment _RARE_
. I-GENE

Exchanging _RARE_
the I-GENE
human O
propeptide _RARE_
in O
this O
chimera _RARE_
with O
either O
the I-GENE
murine I-GENE
MIC _RARE_
- O
1 I-GENE
or O
TGF I-GENE
- O
beta1 I-GENE
propeptide _RARE_
resulted O
in O
secretion O
of I-GENE
the I-GENE
unprocessed _RARE_
, O
monomeric O
chimera _RARE_
, O
suggesting O
a I-GENE
specific I-GENE
interaction I-GENE
between O
the I-GENE
human O
MIC _RARE_
- O
1 I-GENE
propeptide _RARE_
and I-GENE
mature O
peptide I-GENE
. I-GENE

RESULTS O
: I-GENE
The O
analyzed O
fragment O
has O
significant O
activity O
in O
EpCAM _RARE_
positive O
cells O
, O
and I-GENE
it O
is O
regulated O
negatively O
by O
tumor O
necrosis I-GENE
factor O
alpha O
( O
TNFalpha _RARE_
). O

The O
mutant I-GENE
receptors I-GENE
, O
as _RARE_
well _RARE_
as _RARE_
sBMPR _RARE_
- O
IA O
, O
were O
expressed O
as _RARE_
fusion O
proteins I-GENE
with O
thioredoxin _RARE_
in O
Escherichia I-GENE
coli I-GENE
, O
and I-GENE
purified _RARE_
using O
reverse I-GENE
phase O
high I-GENE
performance O
liquid O
chromatography O
( O
RP O
- O
HPLC O
) O
after O
digestion O
with O
enterokinase _RARE_
. I-GENE

The O
dual O
specificity O
kinases I-GENE
mitogen I-GENE
- O
activated I-GENE
protein I-GENE
kinase I-GENE
( O
MAPK I-GENE
) O
kinase I-GENE
( O
MKK _RARE_
) O
7 I-GENE
and I-GENE
MKK4 _RARE_
are O
the I-GENE
only O
molecules I-GENE
known O
to O
directly O
activate O
the I-GENE
stress O
kinases I-GENE
stress O
- O
activated I-GENE
protein I-GENE
kinases I-GENE
( O
SAPKs _RARE_
)/ _RARE_
c I-GENE
- O
Jun I-GENE
N I-GENE
- O
terminal O
kinases I-GENE
( O
JNKs _RARE_
) O
in O
response O
to O
environmental O
or O
mitogenic O
stimuli O
. I-GENE

This O
unique O
work O
needs O
to O
be O
edited _RARE_
critically _RARE_
and I-GENE
afterwards _RARE_
translated O
into O
Urdu _RARE_
and I-GENE
other O
languages _RARE_
for O
the I-GENE
benefit O
of I-GENE
the I-GENE
present O
day O
students O
and I-GENE
scholars _RARE_
. I-GENE

RANTES _RARE_
( O
regulated O
upon O
activation O
, O
normally O
T I-GENE
- O
cell I-GENE
expressed O
and I-GENE
presumably O
secreted O
) O
is O
a I-GENE
CC _RARE_
chemokine _RARE_
which O
recruits _RARE_
and I-GENE
activates O
monocytes O
, O
lymphocytes O
, O
and I-GENE
eosinophils O
, O
all O
cell I-GENE
types O
present O
in O
the I-GENE
lung _RARE_
inflammatory O
infiltrate _RARE_
induced O
by O
RSV _RARE_
infection O
. I-GENE

Gabapentin _RARE_
for O
opiod _RARE_
- O
related I-GENE
myoclonus _RARE_
in O
cancer O
patients O
. I-GENE

Recently O
, O
it O
was O
shown O
that O
purified _RARE_
RAG1 _RARE_
/ O
2 I-GENE
proteins I-GENE
can O
cleave _RARE_
DNA O
hairpins _RARE_
in O
vitro O
, O
but O
the I-GENE
same O
activity O
was O
also O
described O
for O
a I-GENE
protein I-GENE
complex I-GENE
of I-GENE
the I-GENE
DNA O
repair O
proteins I-GENE
Nbs1 _RARE_
/ O
Mre11 _RARE_
/ O
Rad50 _RARE_
. I-GENE

APC I-GENE
- O
resistance O
was O
determined O
with O
a I-GENE
functional O
method O
with O
high I-GENE
sensitivity O
and I-GENE
specificity O
for O
the I-GENE
factor O
V O
Leiden _RARE_
mutation I-GENE
. I-GENE

A I-GENE
picture O
is O
emerging _RARE_
showing O
a I-GENE
gradient O
of I-GENE
function O
among O
p53 I-GENE
, O
p73 _RARE_
, O
p63 _RARE_
ranging O
from I-GENE
tumor O
suppression O
to O
development O
. I-GENE

High O
plasma I-GENE
AVP I-GENE
levels O
observed O
in O
the I-GENE
two O
cases O
suggest O
that O
SSRIs _RARE_
stimulate O
AVP I-GENE
secretion O
, O
thereby O
causing O
SIADH _RARE_
. I-GENE

Mutation O
of I-GENE
the I-GENE
octamer O
element I-GENE
also O
significantly O
reduced O
the I-GENE
ability O
of I-GENE
HDAC1 _RARE_
to O
confer O
repression O
of I-GENE
inducible I-GENE
HLA I-GENE
- O
DRA _RARE_
promoter I-GENE
activation O
. I-GENE

Requirements _RARE_
for O
the I-GENE
nuclear O
- O
cytoplasmic I-GENE
translocation O
of I-GENE
infected O
- O
cell I-GENE
protein I-GENE
0 O
of I-GENE
herpes O
simplex I-GENE
virus I-GENE
1 I-GENE
. I-GENE

The O
system O
, O
designed O
to O
exploit _RARE_
the I-GENE
relatively O
constant O
small I-GENE
intestine O
transit O
time O
, O
consists O
of I-GENE
a I-GENE
drug O
- O
containing O
core O
coated _RARE_
with O
a I-GENE
polymeric _RARE_
matrix _RARE_
formed O
by O
a I-GENE
channeling _RARE_
agent O
( O
NaCl O
, O
mannitol _RARE_
, O
and I-GENE
Emdex _RARE_
) O
and I-GENE
an O
inert _RARE_
polymer _RARE_
( O
Eudragit _RARE_
RS100 _RARE_
). O

The O
activity O
of I-GENE
Rac1 I-GENE
leads O
to O
STAT3 I-GENE
translocation O
to O
the I-GENE
nucleus O
coincident _RARE_
with O
STAT3 I-GENE
- O
dependent O
gene I-GENE
expression _RARE_
. I-GENE

Treatment O
of I-GENE
ischemic O
heart O
disease O
in O
the I-GENE
elderly O

To O
avoid O
misinterpretations _RARE_
, O
special O
reference O
values O
should O
be O
applied O
for O
preadolescents _RARE_
, O
at O
least O
with O
regard O
to O
FVC _RARE_
and I-GENE
FEV1 O
. I-GENE

STUDY _RARE_
OBJECTIVE O
: I-GENE
This O
study O
assessed O
several O
methodological _RARE_
aspects O
related I-GENE
to O
the I-GENE
quality O
of I-GENE
published O
controlled O
clinical O
trials O
( O
CCTs _RARE_
) O
in O
relation O
to O
the I-GENE
participation O
of I-GENE
an O
epidemiologist _RARE_
/ O
biostatistician _RARE_
( O
E I-GENE
/ O
B I-GENE
). O

To O
the I-GENE
best O
of I-GENE
our O
knowledge O
, O
SNTCS _RARE_
is O
highly O
malignant O
. I-GENE

Northern O
blot O
analysis O
with O
one O
of I-GENE
the I-GENE
PARNAs _RARE_
revealed O
a I-GENE
highly O
abundant O
signal O
of I-GENE
approximately O
2 I-GENE
. I-GENE
0 O
kilobases O
( O
kb O
) O
present O
in O
all O
cell I-GENE
lines O
tested O
. I-GENE

The O
effect O
of I-GENE
crude O
oil O
spillage _RARE_
on O
growth I-GENE
, O
productivity _RARE_
and I-GENE
nutrient O
uptake O
of I-GENE
maize O
( O
Zea _RARE_
mays _RARE_
L I-GENE
.) O
was O
assessed O
in O
a I-GENE
pot _RARE_
experiment O
using O
an O
Evwreni _RARE_
manifold _RARE_
sample O
of I-GENE
a I-GENE
petroleum _RARE_
development O
company _RARE_
, O
which O
had O
a I-GENE
specific I-GENE
gravity _RARE_
of I-GENE
0 O
. I-GENE
8778 _RARE_
. I-GENE

10 I-GENE
. I-GENE
0 O
+/- O
2 I-GENE
. I-GENE
0 O
pmol _RARE_
/ O
24 O
h O
, O
P I-GENE
< O
0 O
. I-GENE
01 O
) O
and I-GENE
remained O
elevated O
. I-GENE

Pitx2 _RARE_
rescues _RARE_
the I-GENE
GABAergic _RARE_
differentiation O
defect O
and I-GENE
partially O
rescues _RARE_
the I-GENE
axon _RARE_
guidance _RARE_
and I-GENE
behavioral O
phenotypes O
of I-GENE
unc _RARE_
- O
30 _RARE_
mutants I-GENE
, O
indicating O
a I-GENE
high I-GENE
degree O
of I-GENE
functional O
conservation O
between O
these O
evolutionarily O
related I-GENE
genes I-GENE
. I-GENE

Phosphatidylinositol _RARE_
3 I-GENE
- O
kinase I-GENE
potentiates O
, O
but O
does O
not O
trigger _RARE_
, O
T I-GENE
cell I-GENE
proliferation O
mediated O
by O
the I-GENE
IL I-GENE
- O
2 I-GENE
receptor I-GENE
. I-GENE

In O
addition O
, O
stonin _RARE_
2 I-GENE
binds O
to O
the I-GENE
C2B _RARE_
domains I-GENE
of I-GENE
synaptotagmins _RARE_
I I-GENE
and I-GENE
II I-GENE
. I-GENE

Sequence O
comparison O
and I-GENE
binding I-GENE
studies O
of I-GENE
the I-GENE
18 I-GENE
- O
bp I-GENE
MOK2 _RARE_
- O
binding I-GENE
sites I-GENE
present O
in O
intron O
2 I-GENE
of I-GENE
human O
, O
bovine O
, O
and I-GENE
mouse I-GENE
IRBP _RARE_
genes I-GENE
show O
that O
the I-GENE
3 I-GENE
'- I-GENE
half O
sequence I-GENE
is O
the I-GENE
essential O
core O
element I-GENE
for O
MOK2 _RARE_
binding I-GENE
. I-GENE

Measurements O
were O
obtained O
: I-GENE
( O
i I-GENE
) O
just O
after O
the I-GENE
traumatic _RARE_
exposure O
( O
D0 _RARE_
); O
( O
ii O
) O
3 I-GENE
days O
after O
this O
first O
measurement O
( O
D3 O
); O
and I-GENE
( O
iii O
) O
30 _RARE_
days O
after O
( O
D30 _RARE_
). O

Long _RARE_
- O
term O
results O
with O
MACOP _RARE_
- O
B I-GENE
and I-GENE
radiation O
therapy O
for O
aggressive O
lymphomas O
] O
BACKGROUND O
: I-GENE
Long _RARE_
- O
term O
results O
are O
needed O
to O
evaluate O
chemotherapy O
regimens O
and I-GENE
prognostic O
factors O
in O
non O
- O
Hodgkin O
' I-GENE
s I-GENE
lymphomas O
( O
NHL _RARE_
). O

From O
the I-GENE
above O
results O
, O
we O
might O
infer _RARE_
that O
the I-GENE
seizure O
type I-GENE
of I-GENE
TLE _RARE_
and I-GENE
a I-GENE
high I-GENE
frequency O
of I-GENE
seizure O
are O
two O
major I-GENE
independent O
precipitate _RARE_
factors O
for O
abnormal O
latencies _RARE_
of I-GENE
P300 _RARE_
in O
the I-GENE
epileptic _RARE_
patients O
. I-GENE

Rapamycin _RARE_
( O
FRAP _RARE_
/ O
mTOR _RARE_
inhibitor I-GENE
) O
blocked O
4E _RARE_
- O
BP1 _RARE_
phosphorylation O
causing O
a I-GENE
predominance _RARE_
of I-GENE
the I-GENE
alpha O
( O
hypophosphorylated _RARE_
) O
band O
. I-GENE

We O
investigate O
the I-GENE
reaction O
kinetics O
of I-GENE
small I-GENE
spherical _RARE_
particles O
with O
inertia _RARE_
, O
obeying _RARE_
coalescence _RARE_
type I-GENE
of I-GENE
reaction O
, O
B I-GENE
+ O
B I-GENE
--> _RARE_
B I-GENE
, O
and I-GENE
being O
advected _RARE_
by O
hydrodynamical _RARE_
flows _RARE_
with O
time O
- O
periodic O
forcing _RARE_
. I-GENE

Corticosteroid _RARE_
- O
mediated O
transcriptional O
inhibition O
was O
greater O
for O
MR O
/ O
GR I-GENE
in O
combination O
than O
for O
MR O
or O
GR I-GENE
alone O
. I-GENE

These O
data O
define O
a I-GENE
conserved O
pathway O
wherein _RARE_
sequential O
histone I-GENE
modifications O
establish O
a I-GENE
" I-GENE
histone I-GENE
code O
" I-GENE
essential O
for O
the I-GENE
epigenetic _RARE_
inheritance _RARE_
of I-GENE
heterochromatin _RARE_
assembly O
. I-GENE

The O
bovine O
PGHS _RARE_
- O
2 I-GENE
cDNA O
was O
cloned O
by O
a I-GENE
combination O
of I-GENE
reverse I-GENE
transcription I-GENE
- O
polymerase I-GENE
chain I-GENE
reaction O
and I-GENE
cDNA O
library O
screening O
. I-GENE

Telomerase _RARE_
is O
a I-GENE
ribonucleoprotein I-GENE
complex I-GENE
that O
synthesizes _RARE_
telomeric O
DNA O
onto O
chromosomes O
using O
its O
RNA I-GENE
component _RARE_
as _RARE_
template O
. I-GENE

The O
iterative _RARE_
method O
proposed O
by O
Bengtsson _RARE_
[ _RARE_
Appl _RARE_
. I-GENE

Several O
distinct O
apoptotic O
stimuli O
induce O
the I-GENE
expression _RARE_
and I-GENE
caspase _RARE_
- O
dependent O
cleavage O
of I-GENE
hTAF _RARE_
( O
II I-GENE
) O
80 O
delta I-GENE
. I-GENE
hTAF _RARE_
( O
II I-GENE
) O
80 O
delta I-GENE
, O
unlike O
hTAF _RARE_
( O
II I-GENE
) O
80 O
, O
forms O
a I-GENE
TFIID I-GENE
- O
like I-GENE
complex I-GENE
lacking O
hTAF _RARE_
( O
II I-GENE
) O
31 O
. I-GENE

With O
NEU _RARE_
overexpression O
, O
nodal O
control O
decreased O
from I-GENE
72 O
% O
to O
34 O
% O
( O
p O
= O
. I-GENE
008 _RARE_
). O

The O
mouse I-GENE
platelet I-GENE
- O
derived O
growth I-GENE
factor O
( O
PDGF I-GENE
) O
beta I-GENE
- O
receptor I-GENE
promoter I-GENE
contains O
a I-GENE
CCAAT I-GENE
motif O
, O
and I-GENE
NF I-GENE
- O
Y O
plays O
an O
essential O
role O
in O
its O
transcription I-GENE
. I-GENE

Biol O
. I-GENE

The O
loop O
domain I-GENE
of I-GENE
heat O
shock I-GENE
transcription I-GENE
factor O
1 I-GENE
dictates _RARE_
DNA O
- O
binding I-GENE
specificity O
and I-GENE
responses O
to O
heat O
stress O
. I-GENE

This O
activation O
was O
then O
blocked O
by O
CGS _RARE_
12066A _RARE_
. I-GENE

Among O
the I-GENE
transcription I-GENE
factors O
known O
to O
interact O
with O
Groucho _RARE_
- O
related I-GENE
protein I-GENE
, O
only O
RUNX1 _RARE_
was O
appreciably _RARE_
downregulated _RARE_
by O
E2A _RARE_
- O
HLF _RARE_
. I-GENE

A I-GENE
new O
intron O
of I-GENE
476 _RARE_
base _RARE_
pairs O
was O
found O
in O
the I-GENE
middle _RARE_
of I-GENE
the I-GENE
5 O
'- I-GENE
untranslated O
leader O
sequence I-GENE
and I-GENE
was O
shown O
to O
robustly _RARE_
enhance O
the I-GENE
promoter I-GENE
activity O
. I-GENE

Our O
findings O
further O
our O
understanding O
of I-GENE
how O
ZBP _RARE_
- O
89 O
modulates _RARE_
cell I-GENE
proliferation O
and I-GENE
reveals O
a I-GENE
novel O
mechanism O
by O
which O
the I-GENE
p53 I-GENE
protein I-GENE
is O
stabilized O
. I-GENE

In O
the I-GENE
free O
- O
swimming O
rotatory _RARE_
test O
mice O
spend _RARE_
most O
of I-GENE
the I-GENE
time O
swimming O
close O
to O
the I-GENE
wall O
of I-GENE
the I-GENE
container _RARE_
attempting _RARE_
to O
escape _RARE_
from I-GENE
an O
aversive _RARE_
test O
situation _RARE_
. I-GENE

As O
well _RARE_
, O
mixtures _RARE_
of I-GENE
( O
LA O
)( I-GENE
12 O
) O
with O
the I-GENE
longer O
chain I-GENE
PEs _RARE_
exhibit O
unusual O
biomodal _RARE_
enthalpy _RARE_
variations O
, O
suggesting O
peptide I-GENE
immiscibility _RARE_
in O
thicker _RARE_
gel O
state O
bilayers _RARE_
. I-GENE

At O
the I-GENE
time O
of I-GENE
the I-GENE
blind O
therapeutic O
doses O
, O
Tg _RARE_
- O
off O
values O
ranged O
from I-GENE
8 O
to O
608 _RARE_
microg O
/ O
l O
. I-GENE

Nephrotoxicity _RARE_
after O
orthotopic _RARE_
liver O
transplantation O
in O
cyclosporin O
A I-GENE
and I-GENE
FK O
506 _RARE_
- O
treated O
patients O
. I-GENE

In O
contrast O
to O
MPc3 _RARE_
, O
data O
indicate O
that O
the I-GENE
Pc _RARE_
protein I-GENE
M33 _RARE_
does O
not O
interact O
with O
AF9 _RARE_
. I-GENE

Hydrocoele _RARE_
is O
common O
in O
men O
in O
Wuchereria _RARE_
bancrofti _RARE_
- O
endemic _RARE_
areas O
, O
the I-GENE
treatment O
for O
which O
is O
currently O
surgical O
intervention O
. I-GENE

Of O
the I-GENE
patients O
in O
each O
regimen O
who O
reached O
study O
end O
points O
, O
17 O
of I-GENE
29 O
( O
59 O
%) O
were O
in O
regimen O
A I-GENE
, O
11 O
of I-GENE
20 O
( O
55 O
%) O
were O
in O
regimen O
B I-GENE
, O
and I-GENE
28 _RARE_
of I-GENE
43 _RARE_
( O
65 O
%) O
were O
in O
regimen O
C I-GENE
met O
the I-GENE
treatment O
success O
criterion O
. I-GENE

One O
maternal _RARE_
death _RARE_
, O
reduced O
body O
weight O
, O
and I-GENE
reduced O
weight O
gain O
were O
noted O
at O
the I-GENE
high I-GENE
dose O
; O
confirmed O
pregnancy _RARE_
rates O
were O
84 O
to O
100 O
% O
for O
each O
group O
. I-GENE

Karger _RARE_
AG _RARE_
, O
Basel _RARE_

In O
regards _RARE_
to O
the I-GENE
latter O
activity O
, O
it O
has O
been O
shown O
that O
S3 _RARE_
contains O
vigorous _RARE_
N I-GENE
- O
glycosylase I-GENE
activity O
for O
the I-GENE
removal O
of I-GENE
8 O
- O
oxoguanine _RARE_
residues O
in O
DNA O
that O
leaves O
baseless _RARE_
sites I-GENE
in O
their O
places _RARE_
. I-GENE

We O
describe O
a I-GENE
total O
of I-GENE
39 _RARE_
DEAH _RARE_
helicases _RARE_
in O
these O
four O
species O
. I-GENE

A I-GENE
prospective O
trial O
was O
undertaken O
to O
determine O
( O
1 I-GENE
) O
clinical O
characteristics O
of I-GENE
patients O
with O
chest O
pain O
; O
( O
2 I-GENE
) O
value O
of I-GENE
cardiac I-GENE
markers O
troponin _RARE_
T I-GENE
, O
myoglobin I-GENE
and I-GENE
CK _RARE_
- O
MB O
mass O
in O
differentiating O
cardiac I-GENE
and I-GENE
noncardiac _RARE_
chest O
pain O
; O
( O
3 I-GENE
) O
the I-GENE
proportion O
of I-GENE
patients O
with O
ACS _RARE_
in O
whom O
these O
markers O
provided O
helpful O
additional O
information O
on O
admission O
and I-GENE
afterwards _RARE_
. I-GENE

Inactivity _RARE_
of I-GENE
the I-GENE
human O
cytomegalovirus _RARE_
( O
HCMV _RARE_
) O
major I-GENE
immediate I-GENE
- O
early O
regulatory O
region O
( O
MIERR _RARE_
), O
which O
is O
composed O
of I-GENE
promoter I-GENE
, O
enhancer I-GENE
, O
unique O
region O
, O
and I-GENE
modulator _RARE_
, O
is O
linked O
to O
lack O
of I-GENE
HCMV _RARE_
replication O
in O
latently _RARE_
infected O
cells O
and I-GENE
in O
other O
nonpermissive _RARE_
cell I-GENE
types O
, O
including O
human O
embryonal _RARE_
NTera2 _RARE_
carcinoma O
( O
NT2 _RARE_
) O
cells O
. I-GENE

The O
observed O
triplexes _RARE_
depend O
on O
the I-GENE
length I-GENE
of I-GENE
the I-GENE
repeat I-GENE
. I-GENE

Statistical _RARE_
Analysis O
included O
ANOVA _RARE_
, O
the I-GENE
Pearson _RARE_
Product _RARE_
Moment _RARE_
Correlation _RARE_
Coefficient _RARE_
, O
Principal _RARE_
Components _RARE_
Analysis O
and I-GENE
Discriminant _RARE_
Function _RARE_
Analysis O
and I-GENE
the I-GENE
calculation _RARE_
of I-GENE
Cronbach _RARE_
' I-GENE
s I-GENE
alpha O
( O
alpha O
) O
RESULTS O
: I-GENE
Both O
Sensitivity _RARE_
and I-GENE
specificity O
exceed _RARE_
90 O
. I-GENE
00 O
at O
23 O
/ O
24 O
, O
Chronbach _RARE_
' I-GENE
s I-GENE
alpha O
for O
the I-GENE
total O
scale O
was O
equal O
to O
0 O
. I-GENE
95 _RARE_
. I-GENE

BACKGROUND O
: I-GENE
Previous O
studies O
have O
indicated O
that O
the I-GENE
60 _RARE_
-, O
30 _RARE_
-, O
28 _RARE_
- O
and I-GENE
12 O
- O
item _RARE_
versions _RARE_
of I-GENE
the I-GENE
General _RARE_
Health O
Questionnaire _RARE_
( O
GHQ _RARE_
) O
are O
liable _RARE_
to O
retest _RARE_
effects O
, O
especially O
when O
administered O
multiple O
times O
with O
short O
intervals O
. I-GENE

Cross O
- O
linking O
FcalphaR _RARE_
on O
wt I-GENE
- O
ITAM _RARE_
or O
IIA _RARE_
- O
ITAM _RARE_
cells O
triggered O
equivalent O
PI I-GENE
3 I-GENE
- O
kinase I-GENE
- O
dependent O
activation O
of I-GENE
PKBalpha _RARE_
. I-GENE

An O
F222W _RARE_
: I-GENE
W21F _RARE_
rGST _RARE_
A1 _RARE_
- O
1 I-GENE
double I-GENE
mutant I-GENE
provides O
a I-GENE
direct O
fluorescence O
probe O
of I-GENE
changes O
in O
the I-GENE
environment O
of I-GENE
the I-GENE
C I-GENE
- O
terminal O
residue O
. I-GENE

Binding O
of I-GENE
serum I-GENE
response O
factor O
to O
CArG _RARE_
box I-GENE
sequences O
is O
necessary O
but O
not O
sufficient O
to O
restrict _RARE_
gene I-GENE
expression _RARE_
to O
arterial O
smooth _RARE_
muscle I-GENE
cells O
. I-GENE

They O
consist O
of I-GENE
at O
least O
two O
separable _RARE_
components _RARE_
, O
one O
heat O
stable O
and I-GENE
the I-GENE
other O
heat O
labile _RARE_
. I-GENE

No O
preferential O
VH I-GENE
/ O
VL _RARE_
- O
chains I-GENE
correlated O
with O
any O
of I-GENE
the I-GENE
12 O
different O
antigen I-GENE
reactivities _RARE_
, O
even O
for O
mAbs _RARE_
with O
nearly O
identical O
cross O
- O
reactivities _RARE_
. I-GENE

These O
results O
were O
compared O
with O
the I-GENE
estimates O
of I-GENE
penetration O
from I-GENE
steady O
- O
state O
calculations _RARE_
, O
square O
root O
of I-GENE
time O
calculations _RARE_
, O
and I-GENE
a I-GENE
biologically O
based O
mathematical _RARE_
model O
. I-GENE

Based O
on O
this O
analysis O
, O
we O
propose O
that O
the I-GENE
interactions O
of I-GENE
Sos I-GENE
with O
the I-GENE
switch O
1 I-GENE
and I-GENE
switch O
2 I-GENE
regions O
of I-GENE
Ras I-GENE
have O
distinct O
functional O
consequences O
: I-GENE
the I-GENE
interaction I-GENE
with O
switch O
2 I-GENE
mediates O
the I-GENE
anchoring _RARE_
of I-GENE
Ras I-GENE
to O
Sos I-GENE
, O
whereas O
the I-GENE
interaction I-GENE
with O
switch O
1 I-GENE
leads O
to O
disruption O
of I-GENE
the I-GENE
nucleotide O
- O
binding I-GENE
site I-GENE
and I-GENE
GDP O
dissociation O
. I-GENE

Thus O
, O
the I-GENE
interaction I-GENE
of I-GENE
Tat I-GENE
with O
the I-GENE
components _RARE_
of I-GENE
this O
rel I-GENE
/ O
AP1 I-GENE
cooperative O
complex I-GENE
seems O
to O
induce O
quantitative O
and I-GENE
qualitative O
alterations O
of I-GENE
this O
complex I-GENE
as _RARE_
activation O
progresses _RARE_
, O
resulting O
in O
a I-GENE
decrease O
of I-GENE
IL I-GENE
- O
2 I-GENE
gene I-GENE
transcription I-GENE
. I-GENE

SIT _RARE_
( O
SHP2 _RARE_
- O
interacting O
transmembrane I-GENE
adaptor O
protein I-GENE
) O
is O
a I-GENE
recently O
identified O
transmembrane I-GENE
adaptor O
protein I-GENE
, O
which O
is O
expressed O
in O
lymphocytes O
. I-GENE

In O
this O
manuscript _RARE_
we O
demonstrate O
that O
two O
tandem O
Ets I-GENE
sites I-GENE
in O
the I-GENE
mouse I-GENE
GL _RARE_
alpha O
promoter I-GENE
bind O
the I-GENE
transcription I-GENE
factors O
Elf _RARE_
- O
1 I-GENE
and I-GENE
PU I-GENE
. I-GENE
1 I-GENE
, O
and I-GENE
that O
the I-GENE
3 I-GENE
' I-GENE
site I-GENE
is O
essential O
for O
expression _RARE_
of I-GENE
a I-GENE
luciferase I-GENE
reporter I-GENE
gene I-GENE
driven O
by O
the I-GENE
GL _RARE_
alpha O
promoter I-GENE
. I-GENE

ICA _RARE_
in O
the I-GENE
reference O
solution O
was O
characterised _RARE_
by O
LC _RARE_
and I-GENE
time O
- O
of I-GENE
- O
flight _RARE_
( O
TOF O
) O
MS O
and I-GENE
quantified _RARE_
by O
LC _RARE_
chemiluminescent _RARE_
nitrogen O
detection O
( O
LC _RARE_
- O
CLND _RARE_
). O

These O
disorders O
include O
low O
- O
back O
pain O
, O
saddle _RARE_
anesthesia O
, O
bilateral O
sciatica _RARE_
, O
then O
motor O
weakness _RARE_
of I-GENE
the I-GENE
lower O
extremities _RARE_
or O
chronic O
paraplegia _RARE_
and I-GENE
, O
bladder O
dysfunction O
. I-GENE

C I-GENE
. I-GENE
elegans O
embryogenesis O
begins O
with O
a I-GENE
stereotyped _RARE_
sequence I-GENE
of I-GENE
asymmetric O
cell I-GENE
divisions _RARE_
that O
are O
largely O
responsible O
for O
establishing _RARE_
the I-GENE
nematode O
body O
plan _RARE_
. I-GENE

Additionally O
, O
a I-GENE
CaCO3 _RARE_
- O
CO2 O
/ O
N2 O
buffered _RARE_
solution O
was O
necessary O
to O
maintain O
a I-GENE
pH O
of I-GENE
8 O
. I-GENE

Mss4 _RARE_
also O
acts O
as _RARE_
a I-GENE
relatively O
inefficient O
guanine I-GENE
nucleotide O
exchange O
factor O
( O
GEF _RARE_
). O

Effects O
of I-GENE
3 I-GENE
' I-GENE
terminus O
modifications O
on O
mRNA I-GENE
functional O
decay O
during O
in O
vitro O
protein I-GENE
synthesis _RARE_
. I-GENE

Disciplinary _RARE_
action O
for O
DNA O
violation _RARE_
. I-GENE

This O
is O
necessary O
if O
psychiatric O
diagnoses _RARE_
are O
ultimately _RARE_
going _RARE_
to O
be O
refined _RARE_
and I-GENE
validated _RARE_
against O
biological O
criteria O
. I-GENE

We O
also O
demonstrate O
that O
the I-GENE
spo20 _RARE_
(+) _RARE_
gene I-GENE
product I-GENE
is O
structurally O
homologous O
to O
Saccharomyces I-GENE
cerevisiae I-GENE
Sec14 _RARE_
, O
the I-GENE
major I-GENE
phosphatidylinositol _RARE_
transfer O
protein I-GENE
of I-GENE
budding _RARE_
yeast O
. I-GENE

In O
addition O
, O
another O
derivative O
of I-GENE
pCMVJS21 _RARE_
( O
pCMVJS21DeltaGP _RARE_
) O
in O
which O
the I-GENE
gag I-GENE
, O
pol I-GENE
( O
and I-GENE
orf _RARE_
- O
x O
) O
coding O
sequences O
were O
deleted O
also O
gave O
transformed O
foci _RARE_
. I-GENE

It O
is O
shown O
that O
, O
for O
any O
periodic O
input O
, O
the I-GENE
map O
representing O
the I-GENE
relation O
between O
input O
phases O
at O
consecutive O
discharge O
times O
can O
be O
restricted O
to O
a I-GENE
piecewise _RARE_
continuous O
, O
orientation O
preserving _RARE_
circle _RARE_
map O
. I-GENE

Decreased _RARE_
serum I-GENE
ceruloplasmin _RARE_
and I-GENE
copper O
levels O
in O
cervical O
dystonia _RARE_
. I-GENE

Northern O
blot O
analysis O
of I-GENE
RNAs I-GENE
from I-GENE
a I-GENE
number O
of I-GENE
mouse I-GENE
tissues O
reveals O
that O
Atp6i _RARE_
is O
expressed O
predominantly O
in O
osteoclasts _RARE_
, O
and I-GENE
this O
predominant O
expression _RARE_
was O
confirmed O
by O
reverse I-GENE
- O
transcription I-GENE
polymerase I-GENE
chain I-GENE
reaction O
( O
RT I-GENE
- O
PCR O
) O
assay O
and I-GENE
immunohistochemical O
analysis O
. I-GENE

Behavioural _RARE_
tests O
with O
192 _RARE_
specimen _RARE_
of I-GENE
the I-GENE
roman _RARE_
garden _RARE_
snail _RARE_
Helix _RARE_
pomatia _RARE_
L I-GENE
. I-GENE
were O
performed O
in O
order O
to O
clarify O
whether O
the I-GENE
thermopreferendum _RARE_
of I-GENE
this O
pulmonate _RARE_
is O
influenced O
not O
only O
by O
the I-GENE
temperature O
of I-GENE
the I-GENE
substratum _RARE_
but O
also O
by O
air O
temperature O
. I-GENE

As O
well _RARE_
, O
IFN I-GENE
- O
gamma I-GENE
- O
induced O
expression _RARE_
of I-GENE
IRF I-GENE
- O
1 I-GENE
and I-GENE
its O
binding I-GENE
to O
the I-GENE
IRF I-GENE
element I-GENE
is O
inhibited O
. I-GENE

Baseline _RARE_
BMD O
values O
were O
significantly O
lower O
in O
the I-GENE
oligo _RARE_
- O
amenorrheic _RARE_
group O
than O
in O
the I-GENE
two O
others O
at O
the I-GENE
level O
of I-GENE
lumbar O
spine O
( O
anteroposterior O
view O
: I-GENE
0 O
. I-GENE
941 _RARE_
+/- O
0 O
. I-GENE
039 _RARE_
in O
oligo _RARE_
- O
amenorrheic _RARE_
vs O
1 I-GENE
. I-GENE
077 _RARE_
+/- O
0 O
. I-GENE
029 _RARE_
or O
1 I-GENE
. I-GENE
051 _RARE_
+/- O
0 O
. I-GENE
017 _RARE_
g O
x O
cm O
(- O
2 I-GENE
), O
P I-GENE
< O
0 O
. I-GENE
005 O
, O
in O
the I-GENE
eumenorrheic _RARE_
and I-GENE
contraceptive _RARE_
user _RARE_
groups O
, O
respectively O
) O
but O
not O
in O
weight O
- O
bearing _RARE_
bone I-GENE
such O
as _RARE_
proximal O
and I-GENE
midshaft _RARE_
femur O
. I-GENE

The O
glucose I-GENE
/ O
insulin I-GENE
stimulation O
was O
inhibited O
by O
the I-GENE
addition O
of I-GENE
polyunsaturated _RARE_
fatty I-GENE
acids _RARE_
. I-GENE

We O
report O
the I-GENE
results O
of I-GENE
a I-GENE
detailed O
policy _RARE_
analysis O
comparing O
2 I-GENE
CJD _RARE_
- O
related I-GENE
decisions _RARE_
: I-GENE
a I-GENE
1995 O
recall _RARE_
of I-GENE
blood O
from I-GENE
a I-GENE
donor O
with O
classic _RARE_
CJD _RARE_
and I-GENE
the I-GENE
1999 _RARE_
decision _RARE_
to O
defer _RARE_
donations _RARE_
from I-GENE
individuals O
with O
a I-GENE
6 I-GENE
- O
month O
travel _RARE_
history O
to O
the I-GENE
UK _RARE_
between O
1980 O
and I-GENE
1996 O
due O
to O
concerns _RARE_
related I-GENE
to O
variant I-GENE
CJD _RARE_
. I-GENE

The O
5 O
' I-GENE
flanking I-GENE
sequence I-GENE
of I-GENE
the I-GENE
3B _RARE_
gene I-GENE
is O
extremely O
A I-GENE
+ O
T I-GENE
rich I-GENE
but O
contains O
five O
G I-GENE
/ O
C I-GENE
rich I-GENE
stretches O
, O
each O
approximately O
7bp _RARE_
long I-GENE
, O
which O
have O
strong O
sequence I-GENE
similarity O
to O
the I-GENE
G I-GENE
boxes O
found O
upstream I-GENE
of I-GENE
other O
developmentally O
regulated O
Dictyostelium O
genes I-GENE
. I-GENE

PACAP _RARE_
mRNA I-GENE
was O
widely O
expressed O
in O
most O
human O
tissues O
; O
in O
transfected O
cells O
, O
PACAP _RARE_
was O
diffusely _RARE_
expressed O
in O
the I-GENE
cytoplasm O
. I-GENE

The O
proportion O
of I-GENE
the I-GENE
biopsies O
found O
to O
be O
seropositive O
for O
HBs I-GENE
antigen I-GENE
was O
27 _RARE_
. I-GENE
9 O
%, O
and I-GENE
these O
showed O
either O
MGN _RARE_
or O
MPGN _RARE_
pattern O
. I-GENE

In O
the I-GENE
present O
study O
, O
we O
have O
determined O
the I-GENE
ICBP90 _RARE_
gene I-GENE
structure O
by O
screening O
of I-GENE
a I-GENE
human O
placenta O
genomic O
library O
and I-GENE
PCR O
analysis O
. I-GENE

In O
the I-GENE
stable O
transfectants O
( O
BM3 _RARE_
cells O
) O
expressing O
a I-GENE
mutant I-GENE
bacterial I-GENE
P450 I-GENE
AA O
epoxygenase _RARE_
, O
F87V _RARE_
BM3 _RARE_
, O
which O
was O
genetically O
engineered O
to O
metabolize _RARE_
arachidonic _RARE_
acid O
only O
to O
14 O
, O
15 O
- O
EET _RARE_
, O
AA O
did O
not O
induce O
apoptosis O
and I-GENE
protected O
against O
agonist O
- O
induced O
apoptosis O
. I-GENE

The O
revitalization _RARE_
of I-GENE
surgery O
for O
Parkinson O
' I-GENE
s I-GENE
disease O
( O
PD _RARE_
) O
has O
fueled _RARE_
discussion O
about O
the I-GENE
best O
methodology _RARE_
to O
define O
the I-GENE
target I-GENE
. I-GENE

Foreigners _RARE_
return O
. I-GENE

She _RARE_
drank _RARE_
alcohol _RARE_
once O
or O
twice O
a I-GENE
week O
and I-GENE
regularly _RARE_
took _RARE_
an O
analgesic O
preparation O
, O
containing O
aspirin O
and I-GENE
acetaminophen _RARE_
, O
for O
alleviation _RARE_
of I-GENE
headaches _RARE_
. I-GENE

The O
authors O
did O
not O
detect O
any O
significant O
correlations O
between O
parameters O
of I-GENE
the I-GENE
lipids O
of I-GENE
bone I-GENE
marrow O
and I-GENE
leptin I-GENE
levels O
in O
serum I-GENE
and I-GENE
bone I-GENE
marrow O
. I-GENE

When O
the I-GENE
blood O
clot _RARE_
is O
formed O
in O
the I-GENE
vitreous O
cavity O
, O
intravitreal _RARE_
injection O
of I-GENE
t O
- O
PA I-GENE
can O
convert _RARE_
plasminogen I-GENE
to O
plasmin _RARE_
and I-GENE
remove _RARE_
the I-GENE
clot _RARE_
. I-GENE

When O
this O
CCAAT I-GENE
box I-GENE
was O
inserted O
into O
a I-GENE
heterologous O
promoter I-GENE
construct I-GENE
, O
OA _RARE_
induction O
was O
dependent O
on O
an O
intact O
CCAAT I-GENE
box I-GENE
. I-GENE

Encouraged _RARE_
by O
a I-GENE
Dutch _RARE_
study O
using O
etidronate _RARE_
/ O
fluoride O
in O
corticoid _RARE_
- O
induced O
osteoporosis _RARE_
, O
we O
performed O
a I-GENE
pilot _RARE_
study O
in O
33 O
men O
with O
severe O
established O
primary O
osteoporosis _RARE_
giving O
cyclically _RARE_
etidronate _RARE_
for O
14 O
days O
followed O
by O
fluoride O
plus _RARE_
calcium O
/ O
vitamin O
D O
for O
76 _RARE_
days O
. I-GENE

Far _RARE_
Western O
blot O
analysis O
suggested O
that O
the I-GENE
tandem O
SH2 I-GENE
domains I-GENE
of I-GENE
SHP2 _RARE_
bind O
to O
Gab1 _RARE_
in O
a I-GENE
specific I-GENE
orientation O
, O
in O
which O
the I-GENE
N I-GENE
- O
SH2 I-GENE
domain I-GENE
binds O
to O
phosphotyrosine O
( O
Tyr O
( O
P I-GENE
))- _RARE_
627 _RARE_
and I-GENE
the I-GENE
C I-GENE
- O
SH2 I-GENE
domain I-GENE
binds O
to O
Tyr O
( O
P I-GENE
)- I-GENE
659 _RARE_
. I-GENE

Electrophoretic O
mobility O
shift O
assays O
and I-GENE
coimmunoprecipitation _RARE_
studies O
suggest O
that O
homo _RARE_
- O
and I-GENE
heterodimerization O
occurs O
between O
cKrox _RARE_
family O
members I-GENE
. I-GENE

Expression O
of I-GENE
human O
RACK1 _RARE_
efficiently O
relieves _RARE_
E1A I-GENE
- O
mediated O
growth I-GENE
inhibition O
in O
HF7c _RARE_
and I-GENE
protects _RARE_
human O
tumor O
cells O
from I-GENE
E1A I-GENE
- O
induced O
apoptosis O
. I-GENE

By O
using O
space O
- O
discrete O
/ O
continuous O
metapopulation _RARE_
dynamic O
models O
and I-GENE
computer O
simulations _RARE_
, O
we O
show O
that O
there O
can O
be O
two O
principally _RARE_
different O
regimes _RARE_
of I-GENE
metapopulation _RARE_
dynamics O
. I-GENE

Arterial _RARE_
blood O
gas O
tensions _RARE_
were O
similar O
across O
all O
ventilation O
modes O
. I-GENE

Four O
casein I-GENE
kinase I-GENE
I I-GENE
isoforms I-GENE
are O
differentially O
partitioned _RARE_
between O
nucleus O
and I-GENE
cytoplasm O
. I-GENE

CONCLUSION O
: I-GENE
Extrusion _RARE_
cooking _RARE_
is O
effective O
for O
the I-GENE
inactivation O
of I-GENE
DON _RARE_
but O
is O
of I-GENE
limited O
value O
for O
AFB1 _RARE_
, O
even O
if O
metabisulphite _RARE_
is O
added O
. I-GENE

Also O
, O
the I-GENE
EWS I-GENE
protein I-GENE
stimulates O
transcription I-GENE
mediated O
by O
the I-GENE
COOH O
- O
terminal O
transactivation O
domain I-GENE
of I-GENE
the I-GENE
cofactor I-GENE
CREB I-GENE
- O
binding I-GENE
protein I-GENE
( O
CBP I-GENE
). O

HSF I-GENE
binds O
DNA O
as _RARE_
a I-GENE
trimer _RARE_
, O
and I-GENE
additional O
trimers _RARE_
can O
bind O
DNA O
co O
- O
operatively _RARE_
. I-GENE

Two O
cases O
with O
marked O
chronic O
arm O
lymphoedema _RARE_
reported O
major I-GENE
and I-GENE
persistent O
improvements _RARE_
in O
arm O
volume O
for O
at O
least O
12 O
months O
after O
treatment O
with O
HBO2 _RARE_
. I-GENE

Growth O
hormone I-GENE
and I-GENE
insulin I-GENE
- O
like I-GENE
growth I-GENE
factor O
I I-GENE
receptors I-GENE
in O
the I-GENE
temporomandibular _RARE_
joint O
of I-GENE
the I-GENE
rat O
. I-GENE

Folate _RARE_
metabolism O
in O
the I-GENE
human O
malaria O
parasite O
Plasmodium _RARE_
falciparum O
is O
an O
essential O
activity O
for O
cell I-GENE
growth I-GENE
and I-GENE
replication O
, O
and I-GENE
the I-GENE
target I-GENE
of I-GENE
an O
important O
class O
of I-GENE
therapeutic O
agents O
in O
widespread _RARE_
use O
. I-GENE

These O
results O
indicate O
that O
BACM _RARE_
has O
antiplaque _RARE_
and I-GENE
stronger O
antidegradation _RARE_
effects O
than O
GLCM _RARE_
. I-GENE

A I-GENE
mutation I-GENE
in O
the I-GENE
C I-GENE
domain I-GENE
of I-GENE
Rb I-GENE
, O
L901Q _RARE_
, O
has O
been O
identified O
that O
completely O
abolishes O
cdk4 _RARE_
/ O
D1 I-GENE
phosphorylation O
of I-GENE
the I-GENE
isolated O
C I-GENE
domain I-GENE
. I-GENE

Homo _RARE_
- O
oligomerisation _RARE_
and I-GENE
nuclear O
localisation _RARE_
of I-GENE
mouse I-GENE
histone I-GENE
deacetylase _RARE_
1 I-GENE
. I-GENE

Energy _RARE_
expenditure O
was O
obtained O
using O
a I-GENE
primed O
, O
3 I-GENE
- O
hour O
infusion O
of I-GENE
NaH _RARE_
( O
13 O
) O
CO O
( O
3 I-GENE
'), _RARE_
breath _RARE_
( O
13 O
) O
CO O
( O
2 I-GENE
) O
enrichment _RARE_
determination O
by O
isotope _RARE_
ratio O
mass O
spectroscopy O
, O
and I-GENE
the I-GENE
application O
of I-GENE
a I-GENE
standard O
regression O
equation O
. I-GENE

Fasting _RARE_
gastrin I-GENE
levels O
( O
normal O
range O
: I-GENE
25 O
- O
110 O
mU _RARE_
/ O
L I-GENE
) O
varied O
from I-GENE
48 O
. I-GENE
78 O
mU _RARE_
/ O
L I-GENE
- O
168 _RARE_
. I-GENE
20 O
( O
mean O
: I-GENE
85 _RARE_
. I-GENE
23 O
mU _RARE_
/ O
L I-GENE
). O

Identification O
of I-GENE
pulmonary O
vein O
stenosis O
after O
radiofrequency _RARE_
ablation O
for O
atrial O
fibrillation O
using O
MRI O
. I-GENE

The O
continuing _RARE_
development O
of I-GENE
ligands O
that O
function O
as _RARE_
selective O
estrogens _RARE_
or O
antiestrogens _RARE_
for O
ERalpha _RARE_
or O
ERbeta _RARE_
should O
allow O
optimized _RARE_
tissue I-GENE
selectivity O
of I-GENE
these O
agents O
for O
menopausal _RARE_
hormone I-GENE
replacement O
therapy O
and I-GENE
the I-GENE
treatment O
and I-GENE
prevention O
of I-GENE
breast O
cancer O
. I-GENE

Baseline _RARE_
variables O
associated I-GENE
with O
CD O
included O
a I-GENE
less O
frequent O
use O
of I-GENE
prestroke _RARE_
aspirin O
and I-GENE
a I-GENE
higher O
incidence O
of I-GENE
early O
CT _RARE_
changes O
of I-GENE
edema O
or O
mass O
effect O
or O
dense _RARE_
middle _RARE_
cerebral O
artery O
sign O
. I-GENE

A I-GENE
peculiar _RARE_
people O
: I-GENE
" I-GENE
the I-GENE
physiological O
aspects O
of I-GENE
Mormonism _RARE_
1850 _RARE_
- O
1975 _RARE_
." _RARE_

SH2D1A _RARE_
protein I-GENE
levels O
are O
up O
- O
regulated O
by O
CD40 I-GENE
cross O
- O
linking O
and I-GENE
down O
- O
regulated O
by O
B I-GENE
cell I-GENE
receptor I-GENE
ligation O
. I-GENE

The O
Genescan _RARE_
program O
predicted O
an O
open O
reading O
frame O
of I-GENE
a I-GENE
novel O
, O
intron O
- O
less O
gene I-GENE
adjacent O
to O
the I-GENE
B236 _RARE_
spot _RARE_
that O
encodes O
a I-GENE
putative O
493 _RARE_
- O
amino I-GENE
acid O
protein I-GENE
containing O
the I-GENE
SNAG _RARE_
repressor O
motif O
in O
the I-GENE
NH2 I-GENE
- O
terminal O
region O
and I-GENE
five O
C2H2 _RARE_
- O
type I-GENE
zinc O
finger I-GENE
motifs O
in O
the I-GENE
COOH O
- O
terminal O
half O
. I-GENE

Under O
our O
conditions O
, O
the I-GENE
combination O
O3 _RARE_
/ O
UV O
did O
not O
improve O
the I-GENE
degradation O
rate O
obtained O
by O
ozonation _RARE_
. I-GENE

The O
metabolic O
events O
occurring O
at O
or O
near O
that O
structure O
and I-GENE
involving O
cyclin I-GENE
D3 O
cause O
the I-GENE
translocation O
of I-GENE
ICP0 _RARE_
to O
the I-GENE
cytoplasm O
. I-GENE

In O
the I-GENE
single I-GENE
case O
the I-GENE
restoration _RARE_
of I-GENE
a I-GENE
structured O
daily O
routine O
represents O
the I-GENE
presupposition _RARE_
for O
a I-GENE
cognitive O
therapy O
. I-GENE

Immunofluorescence _RARE_
studies O
in O
C2C12 O
myotubes O
show O
that O
Smad2 _RARE_
and I-GENE
MEF2A _RARE_
co O
- O
localise _RARE_
in O
the I-GENE
nucleus O
of I-GENE
multinuclear _RARE_
myotubes O
during O
differentiation O
. I-GENE

In O
35 O
of I-GENE
those O
patients O
DD _RARE_
was O
measured O
also O
with O
microlatex _RARE_
tests O
-- O
Tinaquant _RARE_
and I-GENE
BC _RARE_
d I-GENE
- O
dimer O
. I-GENE

Simulating _RARE_
the I-GENE
impact O
during O
human O
jumping _RARE_
by O
means O
of I-GENE
a I-GENE
4 I-GENE
- O
degrees O
- O
of I-GENE
- O
freedom _RARE_
model O
with O
time O
- O
dependent O
properties O
. I-GENE

A I-GENE
novel O
approach O
was O
developed O
for O
identifying O
transcription I-GENE
factor O
activities O
associated I-GENE
with O
NGF _RARE_
- O
activated I-GENE
, O
but O
not O
EGF _RARE_
- O
activated I-GENE
, O
signaling O
, O
using O
random O
oligonucleotide O
clones O
from I-GENE
a I-GENE
DNA O
recognition I-GENE
library O
to O
isolate O
specific I-GENE
DNA O
binding I-GENE
proteins I-GENE
from I-GENE
PC12 O
nuclear O
extracts O
. I-GENE

Atheroma _RARE_
appears O
as _RARE_
a I-GENE
very O
low O
signal O
intensity O
area O
on O
2 I-GENE
- O
dimensional O
time O
- O
of I-GENE
- O
flight _RARE_
( O
TOF O
) O
magnetic O
resonance O
( O
MR O
) O
images O
, O
and I-GENE
its O
components _RARE_
have O
various O
signal O
intensities _RARE_
on O
spin O
- O
echo O
( O
SE O
) O
images O
. I-GENE

Finally O
a I-GENE
10 I-GENE
- O
nucleotide O
region O
flanking I-GENE
the I-GENE
exon O
4 I-GENE
protein I-GENE
- O
binding I-GENE
site I-GENE
is O
homologous O
to O
instability _RARE_
elements O
within O
five O
other O
transcripts I-GENE
, O
suggesting O
that O
a I-GENE
common O
coding O
region O
determinant O
may O
exist O
. I-GENE

Chronic O
nutritional O
diseases O
of I-GENE
infectious O
origin O
: I-GENE
an O
assessment O
of I-GENE
a I-GENE
nascent _RARE_
field O
. I-GENE

The O
cut O
- O
off O
percentage O
positivity _RARE_
value O
was O
established O
using O
500 O
brucellosis _RARE_
- O
positive O
and I-GENE
500 O
brucellosis _RARE_
- O
negative O
serum I-GENE
samples O
, O
confirmed O
with O
reference O
to O
the I-GENE
sample O
data O
using O
the I-GENE
indirect O
ELISA O
kit I-GENE
. I-GENE

PROCEDURE _RARE_
: I-GENE
Cannulas _RARE_
were O
surgically O
positioned O
in O
the I-GENE
abomasal _RARE_
body O
and I-GENE
pyloric _RARE_
antrum _RARE_
of I-GENE
each O
calf O
. I-GENE

The O
utilities _RARE_
measured O
in O
our O
study O
can O
be O
applied O
directly O
to O
quality O
- O
of I-GENE
- O
life O
determinations O
in O
clinical O
trials O
of I-GENE
adjuvant O
IFN I-GENE
alpha O
- O
2b _RARE_
to O
measure O
the I-GENE
net _RARE_
benefit O
of I-GENE
therapy O
. I-GENE

Cells _RARE_
lacking O
p116 _RARE_
exhibit O
a I-GENE
striking O
defect O
in O
the I-GENE
formation O
of I-GENE
these O
macropinocytic _RARE_
structures O
, O
a I-GENE
concomitant O
reduction O
in O
the I-GENE
rate O
of I-GENE
fluid O
phase O
pinocytosis _RARE_
, O
a I-GENE
significant O
decrease O
in O
the I-GENE
efficiency O
of I-GENE
chemotactic O
aggregation _RARE_
, O
and I-GENE
a I-GENE
decrease O
in O
cellular I-GENE
F I-GENE
- O
actin I-GENE
content O
. I-GENE

Ectopic _RARE_
expression _RARE_
of I-GENE
the I-GENE
dominant I-GENE
mutant I-GENE
Lg3 _RARE_
allele O
is O
believed O
to O
cause O
the I-GENE
phenotype O
. I-GENE

Specimen _RARE_
mass O
reduction O
increased O
with O
irradiance _RARE_
from I-GENE
19 I-GENE
to O
72 O
% O
of I-GENE
the I-GENE
initial O
mass O
for O
9 O
-- O
31 O
W _RARE_
/ O
cm O
( O
2 I-GENE
), O
respectively O
. I-GENE

Analysis O
of I-GENE
the I-GENE
genome O
sequence I-GENE
revealed O
26 O
, O
588 _RARE_
protein I-GENE
- O
encoding O
transcripts I-GENE
for O
which O
there O
was O
strong O
corroborating _RARE_
evidence O
and I-GENE
an O
additional O
approximately O
12 O
, O
000 _RARE_
computationally _RARE_
derived O
genes I-GENE
with O
mouse I-GENE
matches O
or O
other O
weak O
supporting O
evidence O
. I-GENE

The O
other O
inhibitor I-GENE
was O
a I-GENE
single I-GENE
TAR _RARE_
decoy _RARE_
, O
driven O
by O
the I-GENE
U6 I-GENE
small I-GENE
nuclear O
RNA I-GENE
promoter I-GENE
( O
U6 I-GENE
- O
P I-GENE
). O

By O
comparison O
, O
in O
nontumorigenic _RARE_
Ad5 _RARE_
cells O
, O
class O
I I-GENE
expression _RARE_
is O
high I-GENE
due O
to O
negligible _RARE_
binding I-GENE
of I-GENE
COUP I-GENE
- O
TF I-GENE
and I-GENE
strong O
binding I-GENE
of I-GENE
NF I-GENE
- O
kappaB I-GENE
. I-GENE

Moreover O
, O
a I-GENE
complex I-GENE
containing O
PTP I-GENE
phi _RARE_
, O
paxillin I-GENE
, O
and I-GENE
a I-GENE
paxillin I-GENE
- O
associated I-GENE
tyrosine I-GENE
kinase I-GENE
, O
Pyk2 _RARE_
, O
can O
be O
immunoprecipitated O
from I-GENE
macrophage I-GENE
lysates O
, O
and I-GENE
the I-GENE
catalytic I-GENE
domain I-GENE
of I-GENE
PTP I-GENE
phi _RARE_
selectively O
binds O
paxillin I-GENE
and I-GENE
Pyk2 _RARE_
in O
vitro O
. I-GENE

Our O
previous O
studies O
have O
shown O
that O
SHP I-GENE
- O
1 I-GENE
, O
a I-GENE
SH2 I-GENE
domain I-GENE
- O
containing O
protein I-GENE
- O
tyrosine I-GENE
phosphatase I-GENE
, O
is O
expressed O
not O
only O
in O
cells O
of I-GENE
hematopoietic O
lineages O
, O
but O
also O
in O
many O
non O
- O
hematopoietic O
cells O
under O
the I-GENE
control O
of I-GENE
an O
alternative O
tissue I-GENE
- O
specific I-GENE
promoter I-GENE
, O
P1 O
. I-GENE

Whereas O
Smad2 _RARE_
was O
rapidly O
phosphorylated O
by O
TGF I-GENE
- O
beta I-GENE
and I-GENE
involved O
in O
the I-GENE
initial O
activation O
of I-GENE
Agc _RARE_
expression _RARE_
in O
confluent _RARE_
cells O
, O
Smad2 _RARE_
activation O
was O
not O
required O
for O
maintaining O
the I-GENE
high I-GENE
level O
of I-GENE
Agc _RARE_
expression _RARE_
. I-GENE

The O
astronaut _RARE_
crew _RARE_
operates _RARE_
the I-GENE
payload _RARE_
and I-GENE
documents _RARE_
its O
operation O
. I-GENE

This O
molecule I-GENE
, O
wH22xeGFP _RARE_
, O
consists O
of I-GENE
the I-GENE
entire O
humanized _RARE_
anti I-GENE
- O
FcgammaRI _RARE_
mAb I-GENE
H22 _RARE_
with O
eGFP _RARE_
genetically O
fused O
to O
the I-GENE
C I-GENE
- O
terminal O
end O
of I-GENE
each O
CH3 _RARE_
domain I-GENE
. I-GENE
wH22xeGFP _RARE_
binds O
within O
the I-GENE
ligand O
- O
binding I-GENE
region O
by O
its O
Fc I-GENE
end O
, O
as _RARE_
well _RARE_
as _RARE_
outside O
the I-GENE
ligand O
- O
binding I-GENE
region O
by O
its O
Fab _RARE_
ends O
, O
thereby O
cross O
- O
linking O
FcgammaRI _RARE_
. I-GENE

On O
the I-GENE
other O
hand O
, O
hepatic O
arterial O
infusion O
therapy O
prolongs _RARE_
the I-GENE
survival O
of I-GENE
H3 I-GENE
patients O
only O
. I-GENE

Hepatitis O
B I-GENE
and I-GENE
C I-GENE
seroprevalence _RARE_
rates O
among O
high I-GENE
- O
risk O
adolescents _RARE_
are O
lower O
in O
El _RARE_
Paso _RARE_
than O
in O
other O
similar O
US O
populations O
, O
presenting O
an O
ideal _RARE_
climate _RARE_
for O
prevention O
programs O
. I-GENE

We O
found O
that O
the I-GENE
SOCS _RARE_
box I-GENE
interacted O
with O
Cullin _RARE_
- O
2 I-GENE
and I-GENE
promoted O
ubiquitination O
of I-GENE
TEL _RARE_
- O
JAK2 _RARE_
. I-GENE

A I-GENE
patient O
is O
described O
with O
skin O
lesions O
resembling O
Kaposi O
' I-GENE
s I-GENE
sarcoma O
( O
KS O
). O

Special _RARE_
issues O
devoted _RARE_
to O
the I-GENE
biosynthesis O
of I-GENE
woody _RARE_
plant _RARE_
biopolymers _RARE_
and I-GENE
related I-GENE
substances O
. I-GENE

These O
data O
suggest O
that O
ADAM _RARE_
- O
TS12 _RARE_
may O
play O
roles O
in O
pulmonary O
cells O
during O
fetal _RARE_
development O
or O
in O
tumor O
processes O
through O
its O
proteolytic O
activity O
or O
as _RARE_
a I-GENE
molecule I-GENE
potentially O
involved O
in O
regulation O
of I-GENE
cell I-GENE
adhesion I-GENE
. I-GENE

Progressive _RARE_
study O
and I-GENE
robustness _RARE_
test O
of I-GENE
QSAR _RARE_
model O
based O
on O
quantum _RARE_
chemical O
parameters O
for O
predicting O
BCF _RARE_
of I-GENE
selected O
polychlorinated _RARE_
organic O
compounds O
( O
PCOCs _RARE_
). O

Additional _RARE_
deletion O
mutations O
revealed O
a I-GENE
new O
, O
67 O
- O
amino I-GENE
- O
acid O
functional O
domain I-GENE
within O
the I-GENE
proline O
- O
rich I-GENE
region O
of I-GENE
SLP _RARE_
- O
76 _RARE_
, O
which O
we O
have O
termed O
the I-GENE
P I-GENE
- O
1 I-GENE
domain I-GENE
. I-GENE

Patients O
with O
type I-GENE
III I-GENE
SOD I-GENE
may O
have O
visceral O
hyperalgesia _RARE_
; O
a I-GENE
trial O
of I-GENE
antidepressants _RARE_
or O
a I-GENE
therapeutic O
trial O
with O
botulinum I-GENE
toxin I-GENE
injection O
into O
the I-GENE
ampulla _RARE_
should O
be O
considered O
prior O
to O
more O
invasive O
endoscopic _RARE_
therapy O
. I-GENE

We O
have O
now O
tested O
all O
known O
mammalian I-GENE
Groucho _RARE_
family O
members I-GENE
for O
their O
ability O
to O
interact O
specifically O
with O
individual O
Tcf _RARE_
/ O
Lef _RARE_
family O
members I-GENE
. I-GENE

Body _RARE_
weight O
reduction O
increases O
insulin I-GENE
sensitivity O
and I-GENE
improves _RARE_
both O
blood O
glucose I-GENE
and I-GENE
blood O
pressure O
control O
. I-GENE

Sequence O
analysis O
indicates O
that O
RBP21 _RARE_
shares O
homology I-GENE
with O
other O
retinoblastoma I-GENE
- O
binding I-GENE
proteins I-GENE
in O
the I-GENE
pRb I-GENE
- O
binding I-GENE
motif O
LxCxE _RARE_
at O
the I-GENE
C I-GENE
- O
terminal O
region O
. I-GENE

Tolerance _RARE_
in O
renal _RARE_
transplantation O
after O
allogeneic _RARE_
bone I-GENE
marrow O
transplantation O
- O
6 I-GENE
- O
year O
follow O
- O
up O
. I-GENE

By O
analyzing O
5 O
'- I-GENE
deletion O
insulin I-GENE
promoter I-GENE
- O
reporter I-GENE
constructs I-GENE
in O
transient O
transfections O
of I-GENE
clonal _RARE_
INS _RARE_
- O
1 I-GENE
beta I-GENE
- O
cells O
, O
we O
located O
activating I-GENE
Hh _RARE_
- O
responsive I-GENE
regions O
within O
the I-GENE
rat O
insulin I-GENE
I I-GENE
promoter I-GENE
that O
include O
the I-GENE
glucose I-GENE
- O
response O
elements O
Far _RARE_
( O
E2 I-GENE
) O
and I-GENE
Flat _RARE_
( O
A2 I-GENE
/ O
A3 _RARE_
). O

However O
, O
when O
directed O
to O
the I-GENE
nucleosome _RARE_
by O
fusion O
to O
core O
histone I-GENE
H2A _RARE_
or O
H2B _RARE_
, O
the I-GENE
non O
- O
histone I-GENE
tail O
forms O
an O
MCB _RARE_
that O
appears O
identical O
to O
that O
of I-GENE
the I-GENE
endogenous O
protein I-GENE
. I-GENE

Data O
were O
obtained O
from I-GENE
2 I-GENE
undergraduate _RARE_
student _RARE_
samples O
, O
a I-GENE
self O
- O
report O
group O
( O
n O
= O
132 O
) O
who O
provided O
NEO _RARE_
- O
PI I-GENE
- O
R I-GENE
self O
- O
ratings _RARE_
on O
2 I-GENE
occasions _RARE_
separated O
by O
a I-GENE
7 I-GENE
- O
to O
14 O
- O
day O
interval O
and I-GENE
an O
informant _RARE_
group O
( O
n O
= O
109 _RARE_
) O
who O
provided O
ratings _RARE_
of I-GENE
well _RARE_
- O
known O
friends _RARE_
or O
relatives _RARE_
on O
2 I-GENE
occasions _RARE_
separated O
by O
a I-GENE
6 I-GENE
month O
interval O
. I-GENE

Pulmonary _RARE_
embolectomy _RARE_
and I-GENE
lung _RARE_
transplantation O
are O
the I-GENE
main O
indications _RARE_
for O
the I-GENE
use O
of I-GENE
heart O
- O
lung _RARE_
- O
machine O
. I-GENE

Comparison O
of I-GENE
German _RARE_
language O
versions _RARE_
of I-GENE
the I-GENE
QWB _RARE_
- O
SA O
and I-GENE
SF _RARE_
- O
36 O
evaluating O
outcomes O
for O
patients O
with O
prostate O
disease O
. I-GENE

The O
median O
preoperative O
best O
- O
corrected O
visual O
acuity _RARE_
of I-GENE
0 O
. I-GENE
08 _RARE_
( O
range O
hand O
motions _RARE_
/ O
0 O
. I-GENE
003 _RARE_
to O
0 O
. I-GENE
4 I-GENE
), O
improved O
by O
5 O
lines O
to O
a I-GENE
median O
final O
postoperative O
best O
- O
corrected O
visual O
acuity _RARE_
of I-GENE
0 O
. I-GENE
25 O
( O
range O
0 O
. I-GENE
025 _RARE_
- O
0 O
. I-GENE
5 O
) O
( O
P I-GENE
= O
0 O
. I-GENE
001 O
). O

Angina _RARE_
( O
Q _RARE_
) O
persistence _RARE_
showed O
marked O
associations O
with O
previous O
myocardial O
infarction O
, O
diagnosed O
angina O
, O
electrocardiogram O
ischemia O
, O
and I-GENE
subsequent O
major I-GENE
ischemic O
heart O
disease O
events O
from I-GENE
Q5 _RARE_
onward _RARE_
. I-GENE

Site O
- O
directed O
mutagenesis O
of I-GENE
CAR _RARE_
revealed O
that O
CAR _RARE_
residues O
Leu73 _RARE_
and I-GENE
Lys121 _RARE_
and I-GENE
/ O
or O
Lys123 _RARE_
are O
critical O
contact _RARE_
residues O
, O
with O
Tyr80 _RARE_
and I-GENE
Tyr83 _RARE_
being O
peripherally _RARE_
involved O
in O
the I-GENE
binding I-GENE
interaction I-GENE
with O
the I-GENE
Ad5 _RARE_
, O
Ad9 _RARE_
, O
Ad12 _RARE_
, O
and I-GENE
Ad41L _RARE_
fiber O
knobs _RARE_
. I-GENE

Transforming _RARE_
growth I-GENE
factor O
- O
beta I-GENE
( O
TGF I-GENE
- O
beta I-GENE
) O
induced O
growth I-GENE
arrest O
of I-GENE
cells O
involves O
regulation O
of I-GENE
the I-GENE
activities O
of I-GENE
both O
D O
- O
and I-GENE
E I-GENE
- O
type I-GENE
cyclin I-GENE
kinase I-GENE
complexes O
thought O
to O
be O
mediated O
primarily O
by O
the I-GENE
regulation O
of I-GENE
p15 _RARE_
( O
Ink4b _RARE_
) O
and I-GENE
p27 I-GENE
( O
Kip1 _RARE_
) O
cyclin I-GENE
kinase I-GENE
inhibitors O
. I-GENE

These O
data O
indicate O
that O
the I-GENE
SmSmad2 _RARE_
responds _RARE_
to O
the I-GENE
TGF I-GENE
- O
beta I-GENE
signals O
by O
interaction I-GENE
with O
receptor I-GENE
I I-GENE
, O
which O
phosphorylates O
it O
, O
whereupon _RARE_
it O
translocates _RARE_
into O
the I-GENE
nucleus O
presumably O
to O
regulate O
target I-GENE
gene I-GENE
transcription I-GENE
and I-GENE
consequently _RARE_
elicit O
a I-GENE
specific I-GENE
TGF I-GENE
- O
beta I-GENE
effect O
. I-GENE

We O
propose O
that O
TFOs _RARE_
represent O
a I-GENE
therapeutic O
potential O
to O
specifically O
diminish _RARE_
the I-GENE
expression _RARE_
of I-GENE
c I-GENE
- O
sis _RARE_
/ O
PDGF I-GENE
- O
B I-GENE
proto I-GENE
- O
oncogene I-GENE
in O
various O
pathologic O
settings _RARE_
where O
constitutive O
expression _RARE_
of I-GENE
this O
gene I-GENE
has O
been O
observed O
. I-GENE

The O
increased O
clearance O
observed O
in O
young O
infants O
is O
in O
contrast O
to O
other O
opioids _RARE_
. I-GENE

Peripheral _RARE_
metabolism O
of I-GENE
androgens _RARE_
takes _RARE_
place O
in O
various O
areas O
within O
the I-GENE
pilosebaceous _RARE_
unit I-GENE
, O
as _RARE_
indicated O
by O
local O
differences O
in O
the I-GENE
activities O
of I-GENE
aromatase I-GENE
, O
5alpha _RARE_
- O
reductase I-GENE
as _RARE_
well _RARE_
as _RARE_
of I-GENE
the I-GENE
presence O
of I-GENE
the I-GENE
androgen O
receptors I-GENE
. I-GENE

This O
unique O
location O
of I-GENE
cavernous _RARE_
malformation _RARE_
is O
associated I-GENE
with O
a I-GENE
risk O
of I-GENE
permanent O
loss O
of I-GENE
the I-GENE
vision O
. I-GENE

The O
JHRLSS _RARE_
has O
been O
used O
in O
prior O
studies O
to O
assess O
RLS _RARE_
severity O
, O
but O
has O
not O
previously O
been O
validated _RARE_
in O
relation O
to O
direct O
measures O
of I-GENE
the I-GENE
morbidity O
associated I-GENE
with O
RLS _RARE_
. I-GENE

Consistent O
effects O
on O
pVHL _RARE_
function O
were O
observed O
for O
all O
mutations O
within O
each O
subclass _RARE_
. I-GENE

Interestingly O
, O
the I-GENE
CYP71D20 _RARE_
- O
encoded I-GENE
enzyme I-GENE
activity O
was O
capable O
of I-GENE
converting I-GENE
both O
5 O
- O
epi _RARE_
- O
aristolochene _RARE_
and I-GENE
1 I-GENE
- O
deoxycapsidiol _RARE_
to O
capsidiol _RARE_
in O
vitro O
, O
consistent O
with O
the I-GENE
notion O
that O
this O
P450 I-GENE
enzyme I-GENE
catalyzes O
both O
hydroxylations _RARE_
of I-GENE
its O
hydrocarbon I-GENE
substrate O
. I-GENE

A I-GENE
new O
species O
of I-GENE
Euspondylus _RARE_
is O
described O
based O
on O
a I-GENE
female O
( O
taken O
within O
a I-GENE
bromeliad _RARE_
) O
from I-GENE
Cerro _RARE_
El _RARE_
Humo _RARE_
, O
Sucre _RARE_
, O
northeastern _RARE_
Venezuela _RARE_
. I-GENE

The O
most O
important O
finding O
, O
however O
, O
was O
that O
IMT _RARE_
values O
were O
related I-GENE
with O
24 O
h O
SBP _RARE_
or O
PP _RARE_
standard O
deviation O
( O
P I-GENE
< O
0 O
. I-GENE
001 O
), O
a I-GENE
measure O
of I-GENE
overall O
SBP _RARE_
or O
PP _RARE_
variability O
. I-GENE

In O
addition O
, O
severe O
vision O
loss O
can O
be O
seen O
with O
interferon I-GENE
alfa _RARE_
- O
2b _RARE_
- O
associated I-GENE
retinopathy _RARE_
. I-GENE

FLP _RARE_
and I-GENE
Cre _RARE_
recombinase _RARE_
function O
in O
Xenopus I-GENE
embryos _RARE_
. I-GENE

Keratoconjunctivitis _RARE_
sicca _RARE_
appears O
to O
be O
a I-GENE
common O
ocular O
complication O
and I-GENE
all O
children O
with O
JRA _RARE_
should O
be O
screened O
for O
it O
with O
a I-GENE
comprehensive _RARE_
battery O
of I-GENE
tests O
. I-GENE

Moreover O
, O
PTax _RARE_
expressed O
higher O
background O
activities O
than O
PTF _RARE_
, O
indicating O
that O
the I-GENE
sequence I-GENE
of I-GENE
the I-GENE
synthetic O
regulatory O
region O
can O
influence O
background O
levels O
. I-GENE

After O
allowing O
time O
for O
absorption O
, O
participants _RARE_
completed O
a I-GENE
bridge _RARE_
simulator _RARE_
task O
. I-GENE

The O
cleavage O
site I-GENE
between O
VPg _RARE_
and I-GENE
RNA I-GENE
dependent O
RNA I-GENE
polymerase I-GENE
was O
predicted O
to O
be O
E445 _RARE_
- O
T446 _RARE_
based O
on O
the I-GENE
amino I-GENE
acid O
sequence I-GENE
analysis O
of I-GENE
the I-GENE
polyprotein _RARE_
from I-GENE
different O
sobemoviruses _RARE_
. I-GENE

Conformational _RARE_
changes O
of I-GENE
the I-GENE
ferric _RARE_
uptake O
regulation O
protein I-GENE
upon O
metal O
activation O
and I-GENE
DNA O
binding I-GENE
; O
first O
evidence O
of I-GENE
structural O
homologies O
with O
the I-GENE
diphtheria _RARE_
toxin I-GENE
repressor O
. I-GENE

At O
visit _RARE_
5 O
, O
the I-GENE
isokinetic _RARE_
test O
showed O
impaired O
muscle I-GENE
function O
recovery O
from I-GENE
23 O
% O
to O
32 O
%, O
while O
the I-GENE
manual _RARE_
test O
showed O
almost O
full O
recovery O
. I-GENE

Constitutive _RARE_
phosphorylation O
and I-GENE
nuclear O
localization O
of I-GENE
Smad3 _RARE_
are O
correlated O
with O
increased O
collagen I-GENE
gene I-GENE
transcription I-GENE
in O
activated I-GENE
hepatic O
stellate _RARE_
cells O
. I-GENE

Cholesteryl _RARE_
ester O
transfer O
protein I-GENE
and I-GENE
atherosclerosis O
in O
Japanese O
subjects O
: I-GENE
a I-GENE
study O
based O
on O
coronary O
angiography O
. I-GENE

And _RARE_
, O
most O
importantly _RARE_
, O
reconstitution _RARE_
of I-GENE
a I-GENE
consensus I-GENE
CRE O
, O
within O
the I-GENE
21 O
- O
bp I-GENE
enhancers I-GENE
increases O
binding I-GENE
of I-GENE
CREB I-GENE
/ O
ATF I-GENE
proteins I-GENE
but O
abrogates _RARE_
basal I-GENE
repression O
of I-GENE
LTR I-GENE
- O
directed O
transcription I-GENE
in O
vitro O
. I-GENE

Stable O
transfection O
of I-GENE
human O
CHOP I-GENE
cDNA O
into O
mammary O
carcinoma O
cells O
demonstrated O
that O
CHOP I-GENE
functioned O
not O
as _RARE_
a I-GENE
mediator _RARE_
of I-GENE
hGH I-GENE
- O
stimulated O
mitogenesis _RARE_
but O
rather O
enhanced O
the I-GENE
protection O
from I-GENE
apoptosis O
afforded _RARE_
by O
hGH I-GENE
in O
a I-GENE
p38 I-GENE
MAPK I-GENE
- O
dependent O
manner O
. I-GENE

The O
combination O
of I-GENE
ifosfamide _RARE_
, O
epirubicin _RARE_
and I-GENE
etoposide _RARE_
( O
IEV _RARE_
) O
is O
an O
effective O
salvage _RARE_
regimen O
for O
lymphoproliferative _RARE_
disease O
. I-GENE

Interestingly O
, O
the I-GENE
activity O
of I-GENE
IkappaB _RARE_
kinase I-GENE
( O
IKK _RARE_
- O
beta I-GENE
), O
which O
plays O
an O
essential O
role O
in O
NF I-GENE
- O
kappaB I-GENE
activation O
through O
IkappaB _RARE_
phosphorylation O
, O
was O
largely O
enhanced O
in O
paclitaxel _RARE_
- O
treated O
cells O
, O
detected O
as _RARE_
IkappaBalpha I-GENE
phosphorylation O
. I-GENE

The O
recessive O
hos1 _RARE_
mutation I-GENE
causes O
enhanced O
induction O
of I-GENE
the I-GENE
CBF I-GENE
transcription I-GENE
factors O
by O
low O
temperature O
as _RARE_
well _RARE_
as _RARE_
of I-GENE
their O
downstream O
cold O
- O
responsive I-GENE
genes I-GENE
. I-GENE

Apart _RARE_
from I-GENE
antimicrobial O
properties O
, O
recent O
data O
indicate O
that O
PMN _RARE_
also O
exert O
anti I-GENE
- O
inflammatory O
effects O
by O
stimulation O
and I-GENE
release O
of I-GENE
cytokine O
antagonists O
such O
as _RARE_
interleukin I-GENE
- O
1 I-GENE
receptor I-GENE
antagonist O
( O
IL I-GENE
- O
1ra _RARE_
). O

Early O
indicators O
of I-GENE
the I-GENE
effect O
of I-GENE
a I-GENE
breast O
cancer O
screening O
program O
for O
low O
- O
income _RARE_
women O
. I-GENE

An O
association O
was O
demonstrated O
between O
the I-GENE
expression _RARE_
of I-GENE
aberrantly _RARE_
and I-GENE
/ O
or O
alternatively O
spliced O
mdm2 _RARE_
mRNAs O
and I-GENE
a I-GENE
lack O
of I-GENE
progesterone O
receptor I-GENE
. I-GENE

BACKGROUND O
: I-GENE
Dermoscopy _RARE_
is O
a I-GENE
noninvasive _RARE_
technique O
that O
increases O
the I-GENE
diagnostic O
accuracy O
of I-GENE
pigmented _RARE_
skin O
lesions O
, O
particularly O
improving _RARE_
the I-GENE
diagnosis O
of I-GENE
patients O
with O
cutaneous O
melanoma _RARE_
in O
situ O
( O
CMIS _RARE_
) O
and I-GENE
early O
invasive O
melanoma _RARE_
. I-GENE

Increased O
erythropoietin I-GENE
synthesis _RARE_
in O
patients O
with O
COLD _RARE_
or O
left O
heart O
failure O
is O
related I-GENE
to O
alterations O
in O
renal _RARE_
haemodynamics _RARE_
. I-GENE

The O
( O
two O
- O
motif O
) O
domain I-GENE
fold O
contains O
a I-GENE
pair O
of I-GENE
calcium O
binding I-GENE
sites I-GENE
very O
similar O
to O
those O
found O
in O
a I-GENE
two O
- O
domain I-GENE
prokaryotic O
betagamma _RARE_
- O
crystallin _RARE_
fold O
family O
member _RARE_
, O
Protein I-GENE
S I-GENE
. I-GENE

Twenty O
- O
five O
patients O
also O
received O
PET O
examinations O
during O
the I-GENE
staging _RARE_
procedures O
. I-GENE

In O
the I-GENE
last O
case O
, O
both O
hydroxychloroquine _RARE_
, O
carbamazepine _RARE_
and I-GENE
fluvoxamine _RARE_
had O
a I-GENE
common O
imputability _RARE_
which O
was O
plausible _RARE_
. I-GENE

In O
all O
of I-GENE
these O
cases O
, O
expression _RARE_
of I-GENE
the I-GENE
implicated O
genes I-GENE
was O
absent O
. I-GENE

A I-GENE
subset O
of I-GENE
patients O
( O
n O
= O
30 _RARE_
) O
underwent O
multichannel _RARE_
pressure O
flow O
studies O
, O
which O
demonstrated O
that O
transrectal _RARE_
HIFU _RARE_
reduces O
bladder O
outflow O
obstruction O
. I-GENE

Biochemical O
experiments O
have O
shown O
that O
CopG _RARE_
co O
- O
operatively _RARE_
associates O
to O
its O
target I-GENE
DNA O
at O
low O
protein I-GENE
: I-GENE
DNA O
ratios O
, O
completely O
protecting _RARE_
four O
helical O
turns _RARE_
on O
the I-GENE
same O
face O
of I-GENE
the I-GENE
double I-GENE
helix I-GENE
in O
both O
directions _RARE_
from I-GENE
the I-GENE
inverted O
repeat I-GENE
that O
constitutes O
the I-GENE
CopG _RARE_
primary O
target I-GENE
. I-GENE

The O
mechanism O
of I-GENE
ligand O
- O
activated I-GENE
estrogen I-GENE
receptor I-GENE
alpha O
( O
ERalpha _RARE_
)- I-GENE
dependent O
activation O
of I-GENE
gene I-GENE
expression _RARE_
through O
the I-GENE
SRE O
was O
determined O
by O
mutational O
analysis O
of I-GENE
the I-GENE
promoter I-GENE
, O
analysis O
of I-GENE
mitogen I-GENE
- O
activated I-GENE
protein I-GENE
kinase I-GENE
( O
MAPK I-GENE
) O
pathway O
activation O
by O
E2 I-GENE
, O
and I-GENE
transforming O
growth I-GENE
factor O
alpha O
( O
TGF I-GENE
- O
alpha O
) O
as _RARE_
a I-GENE
positive O
control O
. I-GENE

This O
study O
investigated O
whether O
boron _RARE_
would O
enhance O
the I-GENE
ability O
of I-GENE
17beta _RARE_
- O
estradiol O
( O
E2 I-GENE
) O
or O
parathyroid _RARE_
hormone I-GENE
( O
PTH I-GENE
) O
to O
improve O
bone I-GENE
quality O
in O
ovariectomized _RARE_
OVX _RARE_
rats O
. I-GENE

2001 _RARE_
. I-GENE

The O
Gap69C _RARE_
is O
a I-GENE
single I-GENE
- O
copy O
gene I-GENE
producing O
a I-GENE
major I-GENE
2 I-GENE
. I-GENE
1 I-GENE
- O
kb O
mRNA I-GENE
throughout O
development O
, O
but O
its O
amount O
is O
decreased O
in O
larvae O
. I-GENE

In O
the I-GENE
long I-GENE
term O
, O
questions O
still O
remain _RARE_
about O
whether O
pre I-GENE
- O
dialysis O
rHu _RARE_
EPO I-GENE
either O
speeds _RARE_
up O
or O
delays _RARE_
the I-GENE
onset O
of I-GENE
dialysis O
. I-GENE

The O
validity O
of I-GENE
the I-GENE
FPS _RARE_
- O
R I-GENE
was O
further O
supported O
by O
strong O
positive O
correlations O
with O
the I-GENE
VAS _RARE_
( O
r _RARE_
= O
0 O
. I-GENE
92 O
, O
N I-GENE
= O
45 O
) O
and I-GENE
the I-GENE
CAS O
( O
r _RARE_
= O
0 O
. I-GENE
84 O
, O
N I-GENE
= O
45 O
) O
in O
this O
clinical O
sample O
. I-GENE

The O
BFA _RARE_
System _RARE_
reads _RARE_
a I-GENE
text _RARE_
file _RARE_
with O
flows _RARE_
, O
measured O
with O
fluorescent O
microsphere _RARE_
technique O
, O
and I-GENE
constructs I-GENE
the I-GENE
lung _RARE_
anatomy _RARE_
with O
volumetric _RARE_
pixels _RARE_
showing O
the I-GENE
flows _RARE_
with O
a I-GENE
color O
schema _RARE_
. I-GENE

Therefore O
, O
to O
understand O
how O
ErbB1 _RARE_
/ O
ErbB2 _RARE_
signaling O
contributes O
to O
this O
process O
, O
we O
used O
the I-GENE
ErbB I-GENE
kinase I-GENE
inhibitor I-GENE
AG1478in _RARE_
ErbB2 _RARE_
- O
dependent O
BT _RARE_
- O
474 _RARE_
and I-GENE
SKBR _RARE_
- O
3 I-GENE
human O
breast O
cancer O
cells O
. I-GENE

Deletion O
analyses O
implicate _RARE_
the I-GENE
N I-GENE
- O
terminal O
110 O
amino I-GENE
acids _RARE_
of I-GENE
Grb14 _RARE_
and I-GENE
ankyrin _RARE_
repeats O
10 I-GENE
- O
19 I-GENE
of I-GENE
tankyrase _RARE_
2 I-GENE
in O
mediating O
this O
interaction I-GENE
. I-GENE

Hormonal _RARE_
regulation O
of I-GENE
multiple O
promoters O
of I-GENE
the I-GENE
rat O
mitochondrial I-GENE
glycerol _RARE_
- O
3 I-GENE
- O
phosphate I-GENE
dehydrogenase I-GENE
gene I-GENE
: I-GENE
identification O
of I-GENE
a I-GENE
complex I-GENE
hormone I-GENE
- O
response O
element I-GENE
in O
the I-GENE
ubiquitous O
promoter I-GENE
B I-GENE
. I-GENE

SAMPLE _RARE_
POPULATION _RARE_
: I-GENE
MCB _RARE_
from I-GENE
7 I-GENE
racing _RARE_
Greyhounds _RARE_
euthanatized _RARE_
for O
reasons _RARE_
unrelated O
to O
MCB _RARE_
abnormalities O
. I-GENE

Structural O
studies O
have O
shown O
that O
class O
I I-GENE
major I-GENE
histocompatibility I-GENE
complex I-GENE
( O
MHC I-GENE
)- I-GENE
restricted O
peptide I-GENE
- O
specific I-GENE
T I-GENE
cell I-GENE
receptor I-GENE
( O
TCR I-GENE
)- I-GENE
alpha O
/ O
betas _RARE_
make O
multiple O
contacts O
with O
the I-GENE
alpha1 _RARE_
and I-GENE
alpha2 _RARE_
helices O
of I-GENE
the I-GENE
MHC I-GENE
, O
but O
it O
is O
unclear O
which O
or O
how O
many O
of I-GENE
these O
interactions O
contribute O
to O
functional O
binding I-GENE
. I-GENE

Fans _RARE_
in O
tunnels _RARE_
and I-GENE
open O
windows _RARE_
at O
aboveground _RARE_
locations O
appeared O
to O
greatly O
reduce O
the I-GENE
likelihood O
of I-GENE
high I-GENE
PH3 _RARE_
concentrations O
in O
enclosed _RARE_
areas O
. I-GENE

In O
DNA O
strand O
exchange O
reactions O
using O
oligonucleotides O
, O
we O
found O
that O
Rec2 _RARE_
exhibited O
a I-GENE
pairing _RARE_
bias _RARE_
that O
is O
opposite O
that O
of I-GENE
RecA _RARE_
. I-GENE

A I-GENE
major I-GENE
mechanism O
by O
which O
estrogens _RARE_
prevent O
osteoporosis _RARE_
seems O
to O
be O
repression O
of I-GENE
transcription I-GENE
of I-GENE
NF I-GENE
- O
kappa I-GENE
B I-GENE
target I-GENE
genes I-GENE
, O
such O
as _RARE_
the I-GENE
osteoclast _RARE_
- O
activating I-GENE
cytokines O
interleukin I-GENE
- O
6 I-GENE
and I-GENE
interleukin I-GENE
- O
1 I-GENE
. I-GENE

Linear _RARE_
eight O
- O
or O
nine O
- O
residue O
D O
- O
peptides O
derived O
from I-GENE
the I-GENE
pocket O
- O
binding I-GENE
domain I-GENE
of I-GENE
the I-GENE
cyclic I-GENE
molecules I-GENE
also O
bind O
specifically O
. I-GENE

As O
expected O
, O
homologous O
loxP _RARE_
sequences O
efficiently O
underwent O
Cre _RARE_
- O
mediated O
recombination O
. I-GENE

Multistage _RARE_
models O
and I-GENE
the I-GENE
A I-GENE
- O
bomb _RARE_
survivor _RARE_
data O
: I-GENE
implications O
for O
carcinogenic _RARE_
mechanisms O
? O

The O
results O
indicate O
that O
a I-GENE
more O
differentiated O
diagnosis O
of I-GENE
the I-GENE
molar _RARE_
relationship O
will O
allow O
for O
a I-GENE
more O
causally _RARE_
directed O
correction O
of I-GENE
Class _RARE_
II I-GENE
molar _RARE_
relationship O
. I-GENE

It O
is O
surprising _RARE_
that O
dnaE173 _RARE_
, O
a I-GENE
potent O
mutator _RARE_
mutation I-GENE
specific I-GENE
for O
sequence I-GENE
substitution O
as _RARE_
well _RARE_
as _RARE_
single I-GENE
- O
base _RARE_
frameshift O
, O
did O
not O
enhance O
the I-GENE
frequency O
of I-GENE
the I-GENE
hot O
- O
spot _RARE_
frameshift O
mutation I-GENE
. I-GENE

Hypercalcemia _RARE_
associated I-GENE
with O
elevated O
serum I-GENE
PTH I-GENE
concentration O
indicating O
primary O
hyperparathyroidism _RARE_
was O
found O
in O
7 I-GENE
BC _RARE_
patients O
( O
7 I-GENE
%) O
and I-GENE
in O
none O
of I-GENE
healthy O
women O
or O
patients O
with O
thyroid I-GENE
cancer O
. I-GENE

[ _RARE_
figure _RARE_
: I-GENE
see _RARE_
text _RARE_
] O
The O
Stille _RARE_
coupling O
reaction O
has O
been O
performed O
in O
1 I-GENE
- O
butyl _RARE_
- O
3 I-GENE
- O
methylimidazolium _RARE_
tetrafluoroborate _RARE_
( O
BMIM _RARE_
BF4 _RARE_
), O
a I-GENE
room O
- O
temperature O
ionic O
liquid O
( O
RTIL _RARE_
). O

Examination O
of I-GENE
various O
promoter I-GENE
deletion O
mutants I-GENE
indicated O
that O
SF _RARE_
- O
1 I-GENE
acts O
through O
the I-GENE
proximal O
promoter I-GENE
region O
and I-GENE
upstream I-GENE
promoter I-GENE
sequences O
. I-GENE

ORF1 O
( O
1029 _RARE_
bp I-GENE
; O
EMBL _RARE_
databank _RARE_
, O
Accession _RARE_
No O
. I-GENE

Vector _RARE_
stocks _RARE_
containing O
envelope I-GENE
proteins I-GENE
from I-GENE
three O
different O
SIVmac _RARE_
clones O
, O
namely O
, O
SIVmac239 _RARE_
( O
T I-GENE
- O
lymphocyte I-GENE
tropic _RARE_
[ _RARE_
T I-GENE
- O
tropic _RARE_
]), _RARE_
SIVmac316 _RARE_
( O
macrophage I-GENE
tropic _RARE_
[ _RARE_
M I-GENE
- O
tropic _RARE_
]), _RARE_
and I-GENE
SIVmac1A11 _RARE_
( O
dualtropic _RARE_
), O
were O
tested O
. I-GENE

ISS _RARE_
and I-GENE
the I-GENE
acute O
physiology O
and I-GENE
chronic O
health O
evaluation O
( O
APACHE _RARE_
II I-GENE
) O
calculated O
on O
admission O
. I-GENE

Ga O
- O
67 O
and I-GENE
Tl O
- O
201 O
scintigraphy O
in O
extramedullary _RARE_
plasmacytoma _RARE_
: I-GENE
a I-GENE
case O
report O
. I-GENE

Finally O
, O
there O
are O
a I-GENE
growing O
number O
of I-GENE
arguments _RARE_
favouring _RARE_
the I-GENE
use O
of I-GENE
ACE I-GENE
inhibitors O
very O
early O
in O
patients O
with O
diabetes O
mellitus O
. I-GENE

This O
paper O
describes O
the I-GENE
results O
of I-GENE
an O
initial O
study O
on O
the I-GENE
application O
of I-GENE
linear O
solvation _RARE_
energy O
relationships O
( O
LSERs _RARE_
) O
to O
the I-GENE
prediction O
of I-GENE
internal O
standard O
compounds O
in O
reversed O
- O
phase O
liquid O
chromatographic O
( O
RPLC _RARE_
) O
method O
development O
. I-GENE

A I-GENE
38 O
- O
year O
- O
old O
woman O
with O
ulcerative _RARE_
colitis _RARE_
subsequently O
developed O
sarcoidosis _RARE_
. I-GENE

Blood O
from I-GENE
dams _RARE_
was O
collected O
prior O
to O
inoculation _RARE_
and I-GENE
at O
time O
of I-GENE
necropsy _RARE_
for O
measurement O
of I-GENE
IgM I-GENE
and I-GENE
IgG I-GENE
antibodies I-GENE
to O
M I-GENE
. I-GENE
pulmonis _RARE_
. I-GENE

She _RARE_
has O
since O
developed O
a I-GENE
positive O
anti I-GENE
- O
cardiolipin _RARE_
antibody I-GENE
but O
does O
not O
meet _RARE_
diagnostic O
criteria O
for O
systemic O
lupus O
erythematosis _RARE_
. I-GENE
CONCLUSION O
: I-GENE
The O
presence O
of I-GENE
known O
autoimmune _RARE_
disease O
in O
a I-GENE
woman O
with O
POF _RARE_
should O
not O
dissuade _RARE_
the I-GENE
clinician _RARE_
from I-GENE
evaluating O
for O
a I-GENE
potential O
genetic O
cause O
. I-GENE

The O
mutation I-GENE
experiments O
showed O
that O
the I-GENE
most O
critical O
sequence I-GENE
for O
the I-GENE
repression O
of I-GENE
PTH I-GENE
was O
5 O
'- I-GENE
GGGGGAGGGGAG _RARE_
- O
3 I-GENE
' I-GENE
(+ O
1 I-GENE
to O
+ O
12 O
) O
of I-GENE
PTHSR _RARE_
. I-GENE

Thus O
, O
while O
the I-GENE
folds _RARE_
of I-GENE
all O
Myb I-GENE
domains I-GENE
resemble _RARE_
each O
other O
closely O
, O
the I-GENE
function O
of I-GENE
each O
Myb I-GENE
domain I-GENE
depends O
on O
the I-GENE
amino I-GENE
acid O
residues O
that O
are O
located O
on O
the I-GENE
surface O
of I-GENE
each O
protein I-GENE
. I-GENE

A I-GENE
cDNA O
clone O
encoding O
C2H2 _RARE_
- O
type I-GENE
zinc O
finger I-GENE
protein I-GENE
, O
SCOF _RARE_
- O
1 I-GENE
, O
was O
isolated O
from I-GENE
soybean _RARE_
. I-GENE

The O
purpose O
of I-GENE
this O
study O
was O
to O
evaluate O
simplified _RARE_
methods O
for O
estimation O
of I-GENE
Technetium _RARE_
Tc O
99m O
( O
99mTc O
)- I-GENE
pentetate _RARE_
and I-GENE
orthoiodohippurate _RARE_
I I-GENE
131 O
( O
131I O
- O
OIH _RARE_
) O
plasma I-GENE
clearance O
in O
dogs O
and I-GENE
cats O
with O
1 I-GENE
and I-GENE
2 I-GENE
blood O
samples O
. I-GENE

Sevelamer _RARE_
hydrochloride _RARE_
( O
Renagel _RARE_
) O
is O
a I-GENE
nonabsorbed _RARE_
phosphate I-GENE
- O
binding I-GENE
polymer _RARE_
marketed _RARE_
for O
the I-GENE
treatment O
of I-GENE
hyperphosphatemia _RARE_
in O
adult O
patients O
receiving O
hemodialysis O
. I-GENE

Using O
a I-GENE
novel O
method O
combining _RARE_
chromatin O
immunoprecipitation O
and I-GENE
genomic O
array _RARE_
hybridization O
, O
we O
have O
identified O
a I-GENE
460 _RARE_
- O
kb O
CENP _RARE_
- O
A I-GENE
- O
binding I-GENE
DNA O
domain I-GENE
of I-GENE
a I-GENE
neocentromere _RARE_
derived O
from I-GENE
the I-GENE
20p12 _RARE_
region O
of I-GENE
an O
invdup _RARE_
( O
20p _RARE_
) O
human O
marker O
chromosome O
. I-GENE

Cases _RARE_
of I-GENE
lung _RARE_
cancer O
with O
intramedullary _RARE_
metastasis O
are O
rare O
, O
especially O
those O
diagnosed O
before O
death _RARE_
. I-GENE

Direct _RARE_
current O
polarography _RARE_
and I-GENE
differential O
pulse O
polarographic _RARE_
methods O
have O
been O
developed O
for O
the I-GENE
qualitative O
as _RARE_
well _RARE_
as _RARE_
quantitative O
analysis O
of I-GENE
vitamin O
B1 _RARE_
, O
B2 O
and I-GENE
B6 _RARE_
. I-GENE

Fluorimetric _RARE_
determination O
of I-GENE
methylmercury _RARE_
as _RARE_
an O
ion O
- O
association O
complex I-GENE
with O
rhodamine _RARE_
B I-GENE
in O
the I-GENE
presence O
of I-GENE
iodide _RARE_
. I-GENE

The O
corresponding O
genotype _RARE_
was O
determined O
with O
a I-GENE
restriction O
enzyme I-GENE
- O
based O
assay O
. I-GENE

Patients O
were O
divided O
into O
two O
group O
; O
Control O
group O
A I-GENE
in O
which O
a I-GENE
hot O
- O
water O
circulating O
system O
was O
used O
and I-GENE
group O
B I-GENE
in O
which O
a I-GENE
transtracheal _RARE_
heating _RARE_
and I-GENE
humidification _RARE_
system O
by O
ANAMED _RARE_
HUMITUBE _RARE_
was O
used O
, O
during O
gastric O
cancer O
operation O
. I-GENE

Mental _RARE_
rotation _RARE_
of I-GENE
paired I-GENE
figures _RARE_
engendered _RARE_
activation O
in O
the I-GENE
left O
superior O
parietal _RARE_
lobule _RARE_
and I-GENE
the I-GENE
right O
frontal O
medial O
gyrus O
. I-GENE

Here O
we O
demonstrate O
that O
the I-GENE
Ras I-GENE
- O
activated I-GENE
Raf I-GENE
- O
MEK I-GENE
- O
extracellular I-GENE
signal O
- O
regulated O
kinase I-GENE
( O
ERK I-GENE
) O
signaling O
pathway O
can O
specifically O
control O
the I-GENE
expression _RARE_
of I-GENE
individual O
integrin I-GENE
subunits O
in O
a I-GENE
variety O
of I-GENE
human O
and I-GENE
mouse I-GENE
cell I-GENE
lines O
. I-GENE

These O
TxRE _RARE_
contain O
cyclic I-GENE
AMP I-GENE
- O
responsive I-GENE
elements O
( O
CRE O
), O
but O
, O
remarkably O
, O
the I-GENE
" I-GENE
TGACGTCA _RARE_
" I-GENE
consensus I-GENE
is O
never O
strictly O
conserved O
in O
any O
viral I-GENE
strain O
( O
e _RARE_
. I-GENE
g O
., O
AGACGTCA _RARE_
, O
TGACGGCA _RARE_
, O
TGACCTCA _RARE_
). O

The O
hatcher _RARE_
incubators _RARE_
of I-GENE
both O
companies _RARE_
were O
also O
persistently _RARE_
contaminated O
with O
Salmonella _RARE_
livingstone _RARE_
and I-GENE
Salmonella _RARE_
thomasville _RARE_
in O
company _RARE_
A I-GENE
and I-GENE
with O
Salmonella _RARE_
senftenberg _RARE_
in O
company _RARE_
B I-GENE
. I-GENE

Binding O
of I-GENE
cell I-GENE
type I-GENE
- O
specific I-GENE
nuclear O
proteins I-GENE
to O
the I-GENE
5 O
'- I-GENE
flanking I-GENE
region O
of I-GENE
maize O
C4 _RARE_
phosphoenolpyruvate I-GENE
carboxylase _RARE_
gene I-GENE
confers O
its O
differential O
transcription I-GENE
in O
mesophyll _RARE_
cells O
. I-GENE

Susceptibility _RARE_
to O
ischemia O
- O
induced O
arrhythmias O
was O
lower O
in O
1 I-GENE
- O
week O
diabetics _RARE_
: I-GENE
only O
42 O
% O
of I-GENE
diabetic O
hearts O
exhibited O
ventricular O
tachycardia O
( O
VT O
) O
and I-GENE
16 O
% O
had O
short O
episodes O
of I-GENE
ventricular O
fibrillation O
( O
VF O
) O
as _RARE_
compared O
to O
VT O
100 O
% O
and I-GENE
VF O
70 I-GENE
% O
( O
including O
sustained O
VF O
36 O
%) O
in O
the I-GENE
non O
- O
diabetics _RARE_
( O
P I-GENE
< O
0 O
. I-GENE
05 O
). O

CONCLUSIONS O
: I-GENE
The O
methodology _RARE_
of I-GENE
LHR I-GENE
measurement O
significantly O
influences O
the I-GENE
clinical O
contribution O
of I-GENE
Tl O
- O
201 O
lung _RARE_
uptake O
evaluation O
. I-GENE

The O
authors O
made O
an O
analysis O
of I-GENE
social O
- O
economical _RARE_
conditions O
limiting O
the I-GENE
possibilities O
of I-GENE
rendering _RARE_
cardiosurgical _RARE_
care O
to O
children O
. I-GENE

METHODS O
: I-GENE
Experiments O
testing O
the I-GENE
new O
catheter O
and I-GENE
comparing O
it O
to O
the I-GENE
existing O
catheter O
included O
: I-GENE
( O
1 I-GENE
) O
measurement O
of I-GENE
the I-GENE
laser O
output O
beam O
sizes O
and I-GENE
divergences _RARE_
; O
( O
2 I-GENE
) O
evaluation O
of I-GENE
particulate O
matter O
generation O
during O
ablation O
of I-GENE
atherosclerotic _RARE_
tissue I-GENE
; O
( O
3 I-GENE
) O
measurement O
of I-GENE
ablation O
hole _RARE_
sizes O
and I-GENE
tissue I-GENE
penetration O
rates O
; O
( O
4 I-GENE
) O
histopathologic _RARE_
examination O
of I-GENE
laser O
- O
induced O
in O
vivo O
vessel O
wall O
injury O
. I-GENE

The O
reproductive O
effects O
of I-GENE
the I-GENE
administration O
of I-GENE
4 I-GENE
- O
chloro _RARE_
- O
2 I-GENE
- O
methylphenoxyacetic _RARE_
acid O
( O
MCPA _RARE_
) O
to O
rats O
were O
evaluated O
through O
two O
generations _RARE_
, O
from I-GENE
prior O
to O
mating O
, O
throughout O
mating O
, O
to O
gestation O
and I-GENE
lactation _RARE_
. I-GENE

Here O
we O
suggest O
that O
uvrA _RARE_
and I-GENE
the I-GENE
nucleotide O
excision O
repair O
pathway O
are O
involved O
in O
the I-GENE
repair O
of I-GENE
acid O
- O
induced O
DNA O
damage O
and I-GENE
are O
associated I-GENE
with O
successful O
adaptation O
of I-GENE
S I-GENE
. I-GENE
mutans _RARE_
to O
low O
pH O
. I-GENE

The O
improved O
CSF I-GENE
outflow O
conductance O
may O
increase O
the I-GENE
intracranial _RARE_
compliance O
and I-GENE
thereby O
dampen _RARE_
a I-GENE
pathological O
ICP _RARE_
waveform _RARE_
. I-GENE

These O
studies O
demonstrate O
that O
site I-GENE
- O
specific I-GENE
recognition I-GENE
of I-GENE
the I-GENE
bxd _RARE_
PRE _RARE_
by O
d I-GENE
( O
GA _RARE_
)( I-GENE
n O
) O
repeat I-GENE
binding I-GENE
activities O
mediates O
PcG _RARE_
- O
dependent O
silencing O
. I-GENE

The O
gonadotrope _RARE_
- O
specific I-GENE
and I-GENE
regulated O
expression _RARE_
of I-GENE
the I-GENE
GnRH I-GENE
receptor I-GENE
( O
GnRH I-GENE
- O
R I-GENE
) O
gene I-GENE
is O
dependent O
on O
multiple O
transcription I-GENE
factors O
that O
interact O
with O
the I-GENE
noncanonical _RARE_
GnRH I-GENE
- O
R I-GENE
activating I-GENE
sequence I-GENE
( O
GRAS _RARE_
), O
the I-GENE
activator O
protein I-GENE
- O
1 I-GENE
( O
AP I-GENE
- O
1 I-GENE
) O
element I-GENE
, O
and I-GENE
the I-GENE
steroidogenic _RARE_
factor O
- O
1 I-GENE
( O
SF _RARE_
- O
1 I-GENE
) O
binding I-GENE
site I-GENE
. I-GENE

Before _RARE_
PO3 _RARE_
administration O
, O
more O
than O
half O
( O
57 O
. I-GENE
4 I-GENE
%) O
of I-GENE
the I-GENE
patients O
received O
only O
1 I-GENE
or O
2 I-GENE
antituberculous _RARE_
drugs O
( O
ethambutole _RARE_
and I-GENE
ethionamide _RARE_
or O
ethambutole _RARE_
and I-GENE
oprofloxacin _RARE_
). O

Using O
the I-GENE
presented O
categorical _RARE_
structure O
as _RARE_
domain I-GENE
model O
a I-GENE
prototype O
DSS _RARE_
for O
dipslide _RARE_
urine O
cultures O
has O
been O
developed O
. I-GENE

Conclusion _RARE_
: I-GENE
The O
Lp _RARE_
( O
a I-GENE
) O
levels O
in O
these O
children O
were O
the I-GENE
lower O
ever _RARE_
reported O
. I-GENE

Foxp1 _RARE_
and I-GENE
Foxp2 _RARE_
are O
expressed O
at O
high I-GENE
levels O
in O
the I-GENE
lung _RARE_
as _RARE_
early O
as _RARE_
E12 I-GENE
. I-GENE
5 O
of I-GENE
mouse I-GENE
development O
with O
Foxp2 _RARE_
expression _RARE_
restricted O
to O
the I-GENE
airway O
epithelium O
. I-GENE

Audiological _RARE_
findings O
in O
pregnancy _RARE_
. I-GENE

Children O
who O
developed O
lower O
respiratory O
tract O
infections O
or O
PCP _RARE_
had O
increased O
rates O
of I-GENE
decline O
of I-GENE
CD4 I-GENE
cell I-GENE
counts O
during O
the I-GENE
first O
6 I-GENE
months O
of I-GENE
life O
. I-GENE

A I-GENE
randomized O
mix _RARE_
of I-GENE
180 O
sections O
( O
10 I-GENE
samples O
x O
3 I-GENE
tissues O
x O
3 I-GENE
stains _RARE_
x O
2 I-GENE
) O
gave O
90 O
matched O
pairs O
. I-GENE

Sural _RARE_
nerve O
biopsy O
showed O
mild O
thickening _RARE_
of I-GENE
the I-GENE
perineurium _RARE_
, O
vascular I-GENE
alterations O
with O
inflammatory O
cell I-GENE
infiltration _RARE_
in O
the I-GENE
perineurium _RARE_
, O
and I-GENE
remarkable O
loss O
of I-GENE
large O
and I-GENE
small I-GENE
myelinated _RARE_
fibers O
. I-GENE

OBJECTIVES O
: I-GENE
The O
objective O
of I-GENE
this O
review O
was O
to O
assess O
the I-GENE
effects O
of I-GENE
prophylactic O
prostaglandin _RARE_
use O
in O
the I-GENE
third O
stage _RARE_
of I-GENE
labour O
. I-GENE

Testing _RARE_
was O
associated I-GENE
with O
a I-GENE
history O
of I-GENE
nonsexual _RARE_
risk O
behavior O
, O
increased O
knowledge O
of I-GENE
the I-GENE
hepatitis I-GENE
C I-GENE
virus I-GENE
, O
and I-GENE
healthcare _RARE_
provider _RARE_
communication _RARE_
. I-GENE

Cytomegalovirus _RARE_
, O
Chlamydia O
pneumoniae _RARE_
, O
and I-GENE
Helicobacter _RARE_
pylori _RARE_
IgG I-GENE
antibodies I-GENE
and I-GENE
restenosis _RARE_
after O
stent _RARE_
implantation O
: I-GENE
an O
angiographic O
and I-GENE
intravascular O
ultrasound O
study O
. I-GENE

A I-GENE
5 O
- O
month O
- O
old O
infant O
with O
persistent O
congenital O
stridor _RARE_
and I-GENE
acute O
respiratory O
distress O
is O
presented O
. I-GENE

OBJECTIVE O
: I-GENE
To O
determine O
whether O
RSTD _RARE_
predicts O
coronary O
anatomy _RARE_
during O
acute O
coronary O
occlusion O
. I-GENE

Even _RARE_
if O
the I-GENE
electrocardiographic _RARE_
signs O
are O
subdued _RARE_
, O
the I-GENE
underlying O
blockade O
of I-GENE
I I-GENE
( O
Kr _RARE_
) O
current O
may O
precipitate _RARE_
the I-GENE
occurrence O
of I-GENE
arrhythmia _RARE_
. I-GENE

Acetoin _RARE_
can O
be O
reused _RARE_
by O
the I-GENE
bacteria O
during O
stationary O
phase O
when O
other O
carbon O
sources O
have O
been O
depleted O
. I-GENE

Analysis O
of I-GENE
the I-GENE
promoter I-GENE
sequence I-GENE
revealed O
the I-GENE
presence O
of I-GENE
a I-GENE
major I-GENE
transcriptional O
start O
site I-GENE
, O
a I-GENE
canonical O
TATA O
box I-GENE
and I-GENE
putative O
cis O
regulatory O
elements O
for O
pituitary I-GENE
specific I-GENE
expression _RARE_
as _RARE_
well _RARE_
as _RARE_
an O
E I-GENE
- O
responsive I-GENE
element I-GENE
. I-GENE

IL I-GENE
- O
1beta I-GENE
was O
significantly O
higher O
in O
endometrioma _RARE_
than O
in O
lesions O
of I-GENE
other O
localizations _RARE_
. I-GENE

An O
economic _RARE_
analysis O
using O
West _RARE_
of I-GENE
Scotland _RARE_
Coronary O
Prevention O
Study O
( O
WOSCOPS _RARE_
) O
findings O
indicates O
that O
statin _RARE_
treatment O
would O
have O
prevented O
318 _RARE_
events O
per O
10 I-GENE
, O
000 _RARE_
patients O
in O
a I-GENE
population O
similar O
to O
that O
in O
WOSCOPS _RARE_
( O
average O
1 I-GENE
. I-GENE
5 O
% O
annual O
risk O
of I-GENE
a I-GENE
cardiovascular O
event O
) O
at O
a I-GENE
discounted _RARE_
cost O
per O
life O
- O
year O
gained _RARE_
of I-GENE
20 O
, O
375 _RARE_
pounds _RARE_
($ _RARE_
31 O
, O
818 _RARE_
). O

Hydrogels _RARE_
for O
tissue I-GENE
engineering _RARE_
. I-GENE

No O
mutation I-GENE
of I-GENE
the I-GENE
NRL _RARE_
gene I-GENE
was O
found O
in O
any O
of I-GENE
the I-GENE
two O
families _RARE_
. I-GENE

However O
, O
most O
produced O
significant O
alteration O
of I-GENE
small I-GENE
intestinal _RARE_
permeability O
. I-GENE

Our O
results O
show O
that O
CVN _RARE_
specifically O
recognizes O
with O
nanomolar _RARE_
affinity O
Man _RARE_
( O
9 O
) O
GlcNAc _RARE_
( O
2 I-GENE
) O
and I-GENE
the I-GENE
D1D3 _RARE_
isomer _RARE_
of I-GENE
Man _RARE_
( O
8 O
) O
GlcNAc _RARE_
( O
2 I-GENE
). O

Saccharomyces I-GENE
cerevisiae I-GENE
activates O
a I-GENE
regulatory O
network O
called O
" I-GENE
general O
control O
" I-GENE
that O
provides O
the I-GENE
cell I-GENE
with O
sufficient O
amounts O
of I-GENE
protein I-GENE
precursors O
during O
amino I-GENE
acid O
starvation O
. I-GENE

In O
Saccharomyces I-GENE
cerevisiae I-GENE
, O
entry O
into O
mitosis O
requires O
activation O
of I-GENE
the I-GENE
cyclin I-GENE
- O
dependent O
kinase I-GENE
Cdc28 I-GENE
in O
its O
cyclin I-GENE
B I-GENE
( O
Clb _RARE_
)- I-GENE
associated I-GENE
form O
. I-GENE

Data O
from I-GENE
in O
vitro O
splicing _RARE_
assays O
, O
UV O
crosslinking _RARE_
and I-GENE
RNA I-GENE
- O
binding I-GENE
competition O
experiments O
indicates O
a I-GENE
strong O
correlation O
between O
the I-GENE
binding I-GENE
affinities O
of I-GENE
PSI I-GENE
for O
the I-GENE
SELEX _RARE_
sequences O
and I-GENE
their O
ability O
to O
modulate O
splicing _RARE_
of I-GENE
P I-GENE
element I-GENE
IVS3 _RARE_
in O
vitro O
. I-GENE

The O
sensitivity O
of I-GENE
human O
neuroblastoma O
cells O
SK _RARE_
- O
N I-GENE
- O
SH _RARE_
to O
undergo O
apoptosis O
induced O
by O
thapsigargin _RARE_
was O
examined O
. I-GENE

A I-GENE
., O
Slatkin _RARE_
, O
D O
. I-GENE

Multiparous _RARE_
women O
presented O
higher O
BMI O
( O
P I-GENE
= O
0 O
. I-GENE
01 O
) O
and I-GENE
PBF _RARE_
( O
P I-GENE
= O
0 O
. I-GENE
03 O
) O
compared O
with O
primi _RARE_
- O
and I-GENE
nulliparous _RARE_
groups O
. I-GENE

CONCLUSIONS O
AND O
CLINICAL _RARE_
RELEVANCE _RARE_
: I-GENE
Increased O
cortical O
thickness O
and I-GENE
geometric _RARE_
properties O
of I-GENE
left O
MCB _RARE_
- O
IV I-GENE
and I-GENE
- O
V O
of I-GENE
Greyhounds _RARE_
, O
together O
with O
altered O
turnover O
and I-GENE
orientation O
of I-GENE
osteons _RARE_
in O
the I-GENE
dorsal O
quadrants _RARE_
of I-GENE
left O
MCB _RARE_
, O
are O
site I-GENE
- O
specific I-GENE
adaptive O
responses O
associated I-GENE
with O
asymmetric O
cyclic I-GENE
loading O
as _RARE_
a I-GENE
result O
of I-GENE
racing _RARE_
on O
circular O
tracks _RARE_
. I-GENE

To O
examine O
transcriptional O
regulation O
of I-GENE
the I-GENE
rat O
eIF4E _RARE_
gene I-GENE
, O
2 I-GENE
. I-GENE
1 I-GENE
kB _RARE_
of I-GENE
the I-GENE
rat O
eIF4E _RARE_
promoter I-GENE
region O
was O
cloned O
and I-GENE
the I-GENE
contribution O
of I-GENE
specific I-GENE
elements O
in O
regulating O
transcription I-GENE
was O
determined O
in O
primary O
cultures O
of I-GENE
rat O
cardiocytes _RARE_
and I-GENE
in O
a I-GENE
murine I-GENE
C I-GENE
( O
2 I-GENE
) O
C I-GENE
( O
12 O
) O
myoblast _RARE_
cell I-GENE
line O
. I-GENE

The O
prevalence O
of I-GENE
tobacco I-GENE
dependence O
diagnosed O
according O
to O
the I-GENE
ICD _RARE_
- O
10 I-GENE
criteria O
was O
higher O
in O
alcohol _RARE_
- O
dependent O
individuals O
( O
58 O
. I-GENE
1 I-GENE
%) O
than O
in O
nondrinkers _RARE_
or O
social O
drinkers _RARE_
( O
12 O
. I-GENE
8 O
%). O

Management _RARE_
of I-GENE
postvitrectomy _RARE_
diabetic O
vitreous O
hemorrhage O
with O
tissue I-GENE
plasminogen I-GENE
activator O
( O
t O
- O
PA I-GENE
) O
and I-GENE
volume O
homeostatic _RARE_
fluid O
- O
fluid O
exchanger _RARE_
. I-GENE

Transactivation _RARE_
of I-GENE
oIFNtau _RARE_
enhancer I-GENE
- O
reporter I-GENE
constructs I-GENE
was O
primarily O
regulated O
by O
three O
regions O
containing O
AP I-GENE
- O
1 I-GENE
site I-GENE
, O
GATA _RARE_
like I-GENE
sequence I-GENE
and I-GENE
site I-GENE
( O
s I-GENE
) O
unidentified O
. I-GENE

SELECTION _RARE_
CRITERIA _RARE_
: I-GENE
Randomised _RARE_
controlled O
trials O
of I-GENE
cabergoline _RARE_
versus O
placebo O
in O
patients O
with O
a I-GENE
clinical O
diagnosis O
of I-GENE
idiopathic O
Parkinson O
' I-GENE
s I-GENE
disease O
and I-GENE
long I-GENE
- O
term O
complications O
of I-GENE
levodopa _RARE_
therapy O
. I-GENE

0 O
%) O
and I-GENE
IL I-GENE
- O
12 O
( O
42 O
. I-GENE
6 I-GENE
% O
vs O
. I-GENE

Copyright O
2000 O
John _RARE_
Wiley _RARE_
& O
Sons _RARE_
, O
Ltd _RARE_
. I-GENE

Here O
we O
demonstrate O
that O
native O
MRCK _RARE_
exists O
in O
high I-GENE
- O
molecular O
- O
weight O
complexes O
. I-GENE

METHODS O
: I-GENE
This O
retrospective O
review O
comprised O
2711 _RARE_
eyes O
that O
had O
LASIK _RARE_
between O
September _RARE_
1996 O
and I-GENE
September _RARE_
1999 _RARE_
. I-GENE

Sixty _RARE_
- O
one O
cases O
of I-GENE
cholera _RARE_
, O
all O
caused O
by O
V O
. I-GENE
cholerae O
O1 _RARE_
, O
were O
reported O
. I-GENE

This O
could O
lead O
to O
subsequent O
outbreaks _RARE_
if O
Babesia _RARE_
carrier I-GENE
animals O
were O
to O
be O
introduced O
into O
the I-GENE
herd O
. I-GENE

Instead O
, O
TRPS1 _RARE_
potently _RARE_
and I-GENE
specifically O
represses O
transcriptional O
activation O
mediated O
by O
other O
GATA _RARE_
factors O
. I-GENE

Eliminating _RARE_
any O
subset O
of I-GENE
ASCUS _RARE_
reduces O
the I-GENE
ASCUS _RARE_
/ O
SIL _RARE_
ratio O
but O
also O
significantly O
diminishes _RARE_
the I-GENE
sensitivity O
of I-GENE
the I-GENE
Papanicolaou _RARE_
test O
. I-GENE

In O
order O
to O
overcome O
the I-GENE
false O
positive O
readings _RARE_
that O
are O
possible O
in O
sphincter _RARE_
manometry _RARE_
, O
we O
proposed O
to O
use O
secretin _RARE_
stimulated O
endoscopic _RARE_
ultrasound O
( O
SSEUS _RARE_
) O
to O
measure O
pancreatic O
ductal _RARE_
response O
as _RARE_
an O
adjunctive _RARE_
method O
to O
aid O
and I-GENE
supplement _RARE_
the I-GENE
diagnosis O
. I-GENE

Endovascular _RARE_
aneurysm _RARE_
repair O
with O
the I-GENE
AneuRx _RARE_
stent _RARE_
- O
graft O
is O
safe O
, O
but O
is O
it O
effective O
? O

The O
difference O
of I-GENE
hardness _RARE_
over O
time O
of I-GENE
composite O
specimens O
was O
measured O
using O
Knoop _RARE_
hardness _RARE_
measurements O
taken O
at O
the I-GENE
top O
and I-GENE
bottom _RARE_
surfaces _RARE_
of I-GENE
resin O
specimens O
made O
in O
a I-GENE
Teflon _RARE_
mold _RARE_
the I-GENE
same O
dimensions O
as _RARE_
the I-GENE
cavity O
prepared O
in O
dentin O
. I-GENE

Implications _RARE_
in O
biomonitoring _RARE_
of I-GENE
the I-GENE
observed O
accumulation O
patterns O
, O
especially O
in O
the I-GENE
different O
tissues O
of I-GENE
Posidonia _RARE_
oceanica _RARE_
, O
are O
discussed O
. I-GENE

Based O
on O
mutational O
data O
and I-GENE
possible O
mRNA I-GENE
structure O
, O
we O
hypothesized _RARE_
about O
the I-GENE
effect O
of I-GENE
mRNA I-GENE
structure O
on O
translation I-GENE
of I-GENE
the I-GENE
two O
major I-GENE
C I-GENE
/ O
EBPepsilon _RARE_
isoforms I-GENE
: I-GENE
p32 _RARE_
and I-GENE
p30 _RARE_
. I-GENE

Retinoids _RARE_
participate O
in O
the I-GENE
onset O
of I-GENE
differentiation O
, O
apoptosis O
and I-GENE
the I-GENE
inhibition O
of I-GENE
growth I-GENE
in O
a I-GENE
wide O
variety O
of I-GENE
normal O
and I-GENE
cancerous _RARE_
cells O
. I-GENE

We O
conclude O
that O
RPMS _RARE_
acts O
as _RARE_
a I-GENE
negative O
regulator O
of I-GENE
EBNA2 I-GENE
and I-GENE
Notch I-GENE
activity O
through O
its O
interactions O
with O
the I-GENE
CBF1 I-GENE
- O
associated I-GENE
corepressor _RARE_
complex I-GENE
. I-GENE

Isolated _RARE_
Systolic _RARE_
Hypertension _RARE_
: I-GENE
An O
Update _RARE_
. I-GENE

Transfection O
of I-GENE
EGFP _RARE_
- O
tagged O
DENTT _RARE_
NLS O
deletion O
constructs I-GENE
lacking O
the I-GENE
bipartite O
NLS O
- O
1 I-GENE
were O
excluded O
from I-GENE
the I-GENE
nucleolus _RARE_
. I-GENE

VE O
- O
DEF _RARE_
animals O
had O
significantly O
higher O
( O
p O
< O
0 O
. I-GENE
05 O
) O
levels O
of I-GENE
myocardial O
lipid O
peroxidation O
and I-GENE
lower O
( O
p O
< O
0 O
. I-GENE
05 O
) O
protein I-GENE
thiols _RARE_
following O
I I-GENE
- O
R I-GENE
compared O
to O
the I-GENE
CON _RARE_
animals O
. I-GENE

The O
position O
of I-GENE
the I-GENE
analyst _RARE_
as _RARE_
expert _RARE_
: I-GENE
yesterday _RARE_
and I-GENE
today _RARE_
. I-GENE

Furthermore O
, O
we O
showed O
that O
ERSF _RARE_
including O
NF I-GENE
- O
Y O
and I-GENE
ATF6alpha _RARE_
and I-GENE
/ O
or O
beta I-GENE
and I-GENE
capable O
of I-GENE
binding I-GENE
to O
ERSE _RARE_
is O
indeed O
formed O
when O
the I-GENE
cellular I-GENE
UPR _RARE_
is O
activated I-GENE
. I-GENE

We O
performed O
the I-GENE
present O
study O
to O
clarify O
the I-GENE
relationship O
between O
the I-GENE
DOX _RARE_
binding I-GENE
ability O
(% _RARE_
DB _RARE_
) O
and I-GENE
the I-GENE
histologic O
response O
, O
rate O
of I-GENE
decrease O
in O
tumor O
volume O
of I-GENE
malignant O
soft O
tissue I-GENE
tumors O
after O
preoperative O
chemotherapy O
and I-GENE
prognosis O
. I-GENE

We O
have O
also O
isolated O
and I-GENE
analyzed O
the I-GENE
5 O
' I-GENE
flanking I-GENE
region O
of I-GENE
the I-GENE
pea _RARE_
33RNP _RARE_
gene I-GENE
. I-GENE

We O
have O
previously O
shown O
that O
the I-GENE
adenoviral _RARE_
12S _RARE_
E1A I-GENE
protein I-GENE
modulates _RARE_
the I-GENE
phosphorylation O
status O
of I-GENE
p130 I-GENE
and I-GENE
p107 I-GENE
without O
apparent O
changes O
in O
the I-GENE
cell I-GENE
cycle _RARE_
dependent O
phosphorylation O
of I-GENE
the I-GENE
retinoblastoma I-GENE
protein I-GENE
. I-GENE

Baseline _RARE_
MBF _RARE_
in O
females O
was O
significantly O
( O
P I-GENE
< O
0 O
. I-GENE
001 O
) O
higher O
than O
in O
males O
. I-GENE

Only O
nine O
patients O
were O
offered O
surgery O
( O
six O
were O
resected _RARE_
and I-GENE
three O
were O
found O
inoperable _RARE_
). O

The O
deubiquitinating _RARE_
enzyme I-GENE
DUB _RARE_
- O
2 I-GENE
is O
induced O
in O
response O
to O
IL I-GENE
- O
2 I-GENE
but O
as _RARE_
yet O
its O
function O
has O
not O
been O
determined O
. I-GENE

A I-GENE
split _RARE_
motor O
domain I-GENE
in O
a I-GENE
cytoplasmic I-GENE
dynein I-GENE
. I-GENE

Immunological _RARE_
and I-GENE
biochemical O
characterization O
of I-GENE
streptococcal _RARE_
pyrogenic _RARE_
exotoxins _RARE_
I I-GENE
and I-GENE
J O
( O
SPE _RARE_
- O
I I-GENE
and I-GENE
SPE _RARE_
- O
J O
) O
from I-GENE
Streptococcus O
pyogenes _RARE_
. I-GENE

Five O
modalities O
of I-GENE
nonpharmacologic _RARE_
approaches O
are O
recommended O
at O
present O
for O
lifestyle _RARE_
modification O
and I-GENE
control O
of I-GENE
arterial O
blood O
pressure O
elevation O
: I-GENE
1 I-GENE
) O
weight O
reduction O
to O
ideal _RARE_
body O
weight O
, O
since O
it O
reduces O
risk O
of I-GENE
hypertension O
as _RARE_
well _RARE_
as _RARE_
overall O
cardiovascular O
morbidity O
and I-GENE
mortality O
; O
2 I-GENE
) O
dietary O
sodium O
restriction O
to O
less O
than O
2 I-GENE
g O
a I-GENE
day O
, O
without O
assurance _RARE_
that O
it O
will O
normalize _RARE_
arterial O
pressure O
although O
it O
may O
help O
reduce O
dosage O
and I-GENE
numbers O
of I-GENE
prescribed _RARE_
antihypertensive O
drugs O
; O
3 I-GENE
) O
moderation _RARE_
of I-GENE
alcohol _RARE_
consumption O
to O
less O
than O
1 I-GENE
ounce _RARE_
a I-GENE
day O
; O
4 I-GENE
) O
a I-GENE
regular O
isotonic _RARE_
exercise O
program O
; O
and I-GENE
5 O
) O
cessation O
of I-GENE
tobacco I-GENE
consumption O
. I-GENE

Descriptions _RARE_
of I-GENE
this O
locus I-GENE
would O
allow O
comparison O
with O
functionally O
relevant O
molecular O
genetic O
features O
of I-GENE
other O
species O
' I-GENE
homologous O
loci I-GENE
including O
the I-GENE
single I-GENE
- O
copy O
equid _RARE_
LH I-GENE
/ O
CGbeta _RARE_
gene I-GENE
and I-GENE
the I-GENE
primate O
LHbeta _RARE_
- O
CGbeta _RARE_
gene I-GENE
cluster I-GENE
locus I-GENE
. I-GENE

METHODS O
: I-GENE
One O
hundred O
fourteen _RARE_
consecutive O
patients O
( O
mean O
age O
61 O
years O
) O
with O
focal _RARE_
pancreatic O
masses O
, O
detected O
on O
CT _RARE_
, O
underwent O
EUS _RARE_
- O
FNA _RARE_
by O
using O
a I-GENE
linear O
- O
array _RARE_
echoendoscope _RARE_
and I-GENE
22 O
- O
gauge _RARE_
needles _RARE_
. I-GENE

The O
effects O
of I-GENE
chlordiazepoxide _RARE_
( O
2 I-GENE
. I-GENE
5 O
- O
15 O
. I-GENE
0mg _RARE_
/ O
kg O
), O
a I-GENE
full O
benzodiazepine _RARE_
receptor I-GENE
agonist O
, O
and I-GENE
bretazenil _RARE_
( O
5 O
. I-GENE
0 O
- O
30 _RARE_
. I-GENE
0mg _RARE_
/ O
kg O
), O
a I-GENE
partial O
benzodiazepine _RARE_
receptor I-GENE
agonist O
, O
were O
examined O
in O
the I-GENE
murine I-GENE
elevated O
plus _RARE_
- O
maze _RARE_
paradigm _RARE_
. I-GENE

Acute O
effects O
of I-GENE
LI _RARE_
160 O
( O
extract O
of I-GENE
Hypericum _RARE_
perforatum _RARE_
, O
St _RARE_
John _RARE_
' I-GENE
s I-GENE
wort _RARE_
) O
and I-GENE
two O
of I-GENE
its O
constituents _RARE_
on O
neuroendocrine _RARE_
responses O
in O
the I-GENE
rat O
. I-GENE

Guidelines _RARE_
for O
performing _RARE_
a I-GENE
routine O
spiral _RARE_
assay O
are O
presented O
, O
and I-GENE
alternative O
test O
methods O
intended _RARE_
to O
overcome O
a I-GENE
variety O
of I-GENE
technical _RARE_
difficulties _RARE_
( O
such O
as _RARE_
restricted O
sample O
availability O
, O
sample O
viscosity O
or O
volatility _RARE_
, O
etc O
.) O
are O
recommended O
. I-GENE

An O
additional O
9 O
patients O
achieved O
normal O
levels O
with O
adjunctive _RARE_
drug O
therapy O
. I-GENE

Anti _RARE_
- O
nucleolin _RARE_
mAb I-GENE
was O
used O
to O
confirm O
the I-GENE
antigenic O
properties O
of I-GENE
this O
p95 _RARE_
component _RARE_
. I-GENE

Eliminating _RARE_
any O
subset O
of I-GENE
ASCUS _RARE_
reduces O
the I-GENE
ASCUS _RARE_
/ O
SIL _RARE_
ratio O
but O
also O
significantly O
diminishes _RARE_
the I-GENE
sensitivity O
of I-GENE
the I-GENE
Papanicolaou _RARE_
test O
. I-GENE

Prrp _RARE_
can O
also O
associate O
with O
the I-GENE
EVH1 _RARE_
domain I-GENE
of I-GENE
Mena _RARE_
, O
another O
microfilament _RARE_
- O
associated I-GENE
protein I-GENE
. I-GENE

Experience _RARE_
with O
xylene O
- O
free O
sections O
since O
1995 O
at O
the I-GENE
Vrinnevi _RARE_
Hospital _RARE_
is O
favorable _RARE_
. I-GENE

Acquired _RARE_
antithrombin I-GENE
deficiency O
in O
sepsis O
. I-GENE

SIP1 _RARE_
( O
Smad I-GENE
interacting O
protein I-GENE
1 I-GENE
) O
and I-GENE
deltaEF1 _RARE_
( O
delta I-GENE
- O
crystallin _RARE_
enhancer I-GENE
binding I-GENE
factor O
) O
are O
structurally O
similar O
transcriptional O
repressors _RARE_
. I-GENE

SERS _RARE_
spectra O
were O
obtained O
by O
vacuum _RARE_
evaporation _RARE_
and I-GENE
casting _RARE_
of I-GENE
p O
- O
NTP _RARE_
onto O
silver O
island O
films O
, O
and I-GENE
also O
from I-GENE
colloidal _RARE_
silver O
solutions O
. I-GENE

The O
moduli _RARE_
of I-GENE
elasticity _RARE_
of I-GENE
the I-GENE
gray O
and I-GENE
white _RARE_
matter O
were O
3 I-GENE
. I-GENE
4 I-GENE
+/- O
1 I-GENE
. I-GENE
4 I-GENE
kPa _RARE_
( O
mean O
+/- O
standard O
deviation O
) O
and I-GENE
3 I-GENE
. I-GENE
4 I-GENE
+/- O
0 O
. I-GENE
9 O
kPa _RARE_
in O
the I-GENE
axial O
section O
, O
3 I-GENE
+/- O
0 O
. I-GENE
3 I-GENE
kPa _RARE_
and I-GENE
3 I-GENE
. I-GENE
5 O
+/- O
0 O
. I-GENE
5 O
kPa _RARE_
in O
the I-GENE
frontal O
section O
, O
and I-GENE
3 I-GENE
. I-GENE
5 O
+/- O
0 O
. I-GENE
9 O
kPa _RARE_
and I-GENE
2 I-GENE
. I-GENE
8 O
+/- O
0 O
. I-GENE
4 I-GENE
kPa _RARE_
in O
the I-GENE
sagittal _RARE_
section O
, O
respectively O
. I-GENE

[ _RARE_
Clinical O
and I-GENE
epidemiological O
characteristics O
of I-GENE
squamous O
cell I-GENE
carcinoma O
of I-GENE
the I-GENE
oral O
cavity O
in O
women O
] O
BACKGROUND O
: I-GENE
Squamous _RARE_
cell I-GENE
carcinoma O
( O
SCC _RARE_
) O
of I-GENE
the I-GENE
oral O
cavity O
occurs O
mainly O
in O
the I-GENE
male O
population O
. I-GENE

The O
core O
promoter I-GENE
of I-GENE
human O
thioredoxin _RARE_
reductase I-GENE
1 I-GENE
: I-GENE
cloning O
, O
transcriptional O
activity O
, O
and I-GENE
Oct I-GENE
- O
1 I-GENE
, O
Sp1 I-GENE
, O
and I-GENE
Sp3 I-GENE
binding I-GENE
reveal O
a I-GENE
housekeeping O
- O
type I-GENE
promoter I-GENE
for O
the I-GENE
AU _RARE_
- O
rich I-GENE
element I-GENE
- O
regulated O
gene I-GENE
. I-GENE

Phase O
II I-GENE
trial O
of I-GENE
the I-GENE
anti I-GENE
- O
G I-GENE
( O
D2 _RARE_
) O
monoclonal O
antibody I-GENE
3F8 _RARE_
and I-GENE
granulocyte I-GENE
- O
macrophage I-GENE
colony I-GENE
- O
stimulating I-GENE
factor O
for O
neuroblastoma O
. I-GENE

A I-GENE
log O
- O
linear O
dose O
- O
response O
was O
obtained O
for O
the I-GENE
average O
increase O
in O
FEV1 O
up O
to O
6 I-GENE
h O
( O
AUC0 _RARE_
- O
6 I-GENE
h O
) O
and I-GENE
peak O
FEV1 O
across O
the I-GENE
dose O
range O
administered O
by O
Respimat _RARE_
. I-GENE

Plasma I-GENE
DHE _RARE_
concentration O
rose O
promptly _RARE_
above O
5 O
ng O
/ O
ml O
after O
the I-GENE
application O
of I-GENE
the I-GENE
PSA I-GENE
tape _RARE_
onto O
the I-GENE
damaged O
skin O
in O
hairless _RARE_
rat O
. I-GENE

A I-GENE
complete O
drug O
history O
was O
compiled _RARE_
, O
specifying _RARE_
the I-GENE
amount O
and I-GENE
duration O
of I-GENE
VGB _RARE_
medication O
. I-GENE

Epithelial _RARE_
cytotoxicity O
of I-GENE
combined O
antibiotics O
was O
additive O
, O
with O
no O
evidence O
of I-GENE
competition O
or O
synergism _RARE_
. I-GENE

In O
Cd O
- O
spiked _RARE_
OECD _RARE_
soil _RARE_
, O
internal O
Cd O
levels O
were O
linearly _RARE_
related I-GENE
to O
external O
Cd O
concentrations O
, O
whereas O
the I-GENE
springtails _RARE_
maintained O
fixed O
internal O
levels O
of I-GENE
Cu O
and I-GENE
Zn O
regardless O
of I-GENE
spiked _RARE_
concentrations O
. I-GENE

Interestingly O
, O
the I-GENE
similarities O
with O
the I-GENE
endophilin _RARE_
proteins I-GENE
cover _RARE_
the I-GENE
entire O
sequence I-GENE
of I-GENE
the I-GENE
SH3GLB _RARE_
family O
, O
suggesting O
a I-GENE
common O
fold O
and I-GENE
presumably O
a I-GENE
common O
mode O
of I-GENE
action O
. I-GENE

Reovirus _RARE_
mRNAs O
are O
efficiently O
translated O
within O
host O
cells O
despite O
the I-GENE
absence O
of I-GENE
3 I-GENE
' I-GENE
polyadenylated O
tails O
. I-GENE

Grippers _RARE_
with O
integrated O
piezoresistive _RARE_
force O
sensors _RARE_
and I-GENE
with O
attached O
strain O
gauges _RARE_
have O
been O
reported O
. I-GENE

Both O
Z I-GENE
and I-GENE
R I-GENE
expression _RARE_
resulted O
in O
PML _RARE_
dispersion O
in O
EBV O
- O
positive O
cells O
. I-GENE

The O
small I-GENE
copepod _RARE_
Pseudonychocamptus _RARE_
proximus _RARE_
progressively _RARE_
replaced O
the I-GENE
large O
Tisbe _RARE_
furcata _RARE_
in O
sand _RARE_
filters _RARE_
during O
the I-GENE
fall O
of I-GENE
1995 O
and I-GENE
was O
responsible O
for O
the I-GENE
large O
increase O
in O
meiofaunal _RARE_
biomass _RARE_
observed O
after O
spring _RARE_
1996 O
. I-GENE

Evidence O
- O
based O
care O
: I-GENE
a I-GENE
new O
formula O
for O
an O
old O
problem O
? O

Nrf2 _RARE_
regulates O
expression _RARE_
of I-GENE
genes I-GENE
encoding O
enzymes _RARE_
with O
antioxidant O
( O
e _RARE_
. I-GENE
g O
. I-GENE
heme O
oxygenase I-GENE
- O
1 I-GENE
( O
HO _RARE_
- O
1 I-GENE
)) O
or O
xenobiotic _RARE_
detoxification _RARE_
( O
e _RARE_
. I-GENE
g O
. I-GENE

Workload _RARE_
, O
UAPs _RARE_
, O
and I-GENE
you _RARE_
. I-GENE

RESULTS O
: I-GENE
At O
latest _RARE_
examination O
, O
mean O
UPDRS _RARE_
II I-GENE
and I-GENE
III I-GENE
scores O
had O
improved O
by O
30 _RARE_
% O
( O
on O
stimulation O
, O
off O
therapy O
) O
with O
mean O
50 O
% O
reduction O
in O
daily O
off O
time O
. I-GENE

Perfusion _RARE_
technique O
for O
perfusion O
- O
assisted _RARE_
direct O
coronary O
artery O
bypass O
( O
PADCAB _RARE_
). O

Copyright O
2001 _RARE_
Academic O
Press O
. I-GENE

The O
amount O
of I-GENE
drained _RARE_
effusion _RARE_
was O
measured O
, O
and I-GENE
fluid O
was O
sent _RARE_
for O
diagnostic O
assessment O
. I-GENE

